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General introduction 
1.1 Epidemiology of breast cancer 
Breast cancer is one of the most frequently diagnosed cancers and the second leading cause of 
death in Western women. In 2012, this disease was diagnosed in nearly 1.7 million women 
and was responsible for more than 521,900 deaths Worldwide
1
. In the United States, the 
estimated number of new cases was 231,840 in 2015, accounting for 29% of all new cancers 
in women
2
. The incidence of breast cancer is rising in most countries and is expected to rise 
even further in the next 20 years
3,4
. However, survival of patients with breast cancer has 
increased, due to earlier detection and more effective treatment modalities amongst others
5
. 
International variation exists in breast cancer incidence rates. Rates are high in developed 
countries in Northern America and Northern and Western Europe, whereas rates are low in 
most of Africa and Asia. However, breast cancer incidence rates have been rising in countries 
with low rates in recent years as well due to altered reproductive behavior, increased obesity 
and decreased physical activity
1
. The risk of developing breast cancer is related to many 
factors such as age, gender, lifestyle, family history of breast cancer and so on. The 
reproductive risk factors including estrogen exposure are associated with breast cancer risk
6
.  
 
1.2 Breast cancer subtypes 
Breast cancer is a hormonal regulated disease. The majority of breast cancers express the 
receptors for the hormones estrogen and progesterone. Estrogens have been demonstrated to 
be breast carcinogens and they stimulate (tumor) cell growth and thus play an important role 
in the development of breast cancer. Furthermore, estrogen exposure is associated with the 
risk to develop breast cancer
6,7
. The effects of estrogen are mediated by binding to its nuclear 
receptors. There are two different genes coding for two estrogen receptors ER-α and ER-β. 
ER-α (ER) is required for normal mammary gland development, and is of important clinical 
relevance for breast cancer; the role of ER-β is less well defined if relevant for breast cancer 
biology at all. Progesterone binds to the nuclear progesterone receptors (PR) which has two 
different isoforms, PRA and PRB. The expression of PR is regulated by estrogens via ER and 
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PR expression is considered an indicator of an intact estrogen-ER pathway in breast cancer
8
. 
Importantly, breast cancers behave differently depending on ER and PR expression. 
Since human breast cancer is a heterogeneous disease and breast cancer patients are 
diverse in their prognosis and responsiveness to treatments, it is important to classify breast 
cancers in order to provide patients with personalized treatment. Based on gene expression 
profiling, breast cancers are classified into five molecular/intrinsic subtypes: luminal A, 
luminal B, HER2+, basal and normal-like breast cancer (Figure 1.1)
9
. ER is the major 
classifier since tumors of the luminal A and luminal B subtypes are predominantly ER 
positive, while basal and normal-like subtypes are mostly ER negative. Luminal subtype 
tumors are characterized by the expression of ER, PR, Bcl-2, CK8/18 and GATA3. Luminal A 
tumors, however, express higher levels of ER and GATA3 proteins and most ER regulated 
genes, whereas luminal B subtype tumors express relatively lower levels of ER and its target 
genes
10
. Moreover, Ki67, a proliferation marker, is important in the distinction between the 
luminal A and luminal B subtypes
11
 with luminal B subtype tumors expressing higher levels 
of the Ki67 protein. Tumors of the HER2+ subtype are characterized by overexpressing 
HER2 and can be subdivided into two distinct subtypes based on the expression of ER. 
Tumors of the basal-like subtype usually lack ER, PR and HER2 expression and express 
CK5/6 and/or EGFR
12
. Basal-like breast carcinoma has a high expression of the basal gene 
cluster and a high rate of TP53 mutations
13
. Tumors of the normal-like subtype generally lack 
ER, PR, HER2, CK5 and EGFR expression, and have a high expression of genes 
characteristic of parenchymal basal epithelial cells and mesenchymal cells
14
. Claudin-low 
tumors represent a subset of the basal- and normal-like subtypes
15
. They are characterized by 
the low gene expression of claudin-3, -4 and -7, E-cadherin and luminal genes. Moreover, 
Claudin-low tumors are enriched in epithelial-to-mesenchymal transition (EMT) genes and 
cancer stem cell-like markers
16
. Basal and normal-like cancers, often lack ER, PR and HER2 
expression, the latter being referred to as triple-negative breast cancers (TNBCs), and account 
for 10 to 20% of all breast cancers. Since TNBC represents a heterogeneous group of breast 
cancers, gene expression analysis identified six molecular subtypes within TNBCs: basal-like 
1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal 
11 | P a g e  
 
stem-like (MSL), and luminal androgen receptor (LAR) subtypes
17
. 
The different molecular subtypes were shown to be associated with different prognosis
14
. 
For example, within the luminal subgroup patients with tumors of the luminal A subtype have 
the best prognosis, whereas luminal B tumors present with a more aggressive phenotype and 
have a worse prognosis compared with luminal A tumors. Furthermore, the HER2+ and 
basal-like subtypes are less differentiated and have a poor prognosis
18
.  
 
Figure 1.1 Schematic drawing of the molecular/intrinsic breast cancer subtypes. 
 
 
 
1.3 Genetics of breast cancer 
Breast cancer arises as a consequence of genetic mutations in a subset of genes including 
somatic and germline mutations.  
 
1.3.1 Sporadic breast cancer 
All cancers carry somatic mutations, however, sporadic breast cancer develops only from 
somatic mutations and accounts for the majority of breast cancers (around 85%)
19
. Moreover, 
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somatic mutations occur in the genomes of a single cell accumulate over the lifetime of a 
multicellular organism and may be the cumulative result of DNA damage and repair 
processes. A large number of somatic mutations have been identified and global sequencing 
projects have generated catalogs of somatic mutations from these
20
. Around 5 million 
mutations have been identified from 7,042 tumor samples of 30 different classes
21
. There are 
two different types of somatic mutations: ‘driver’ and ‘passenger’ mutations. The driver 
mutations are implicated in oncogenesis, provide the growth advantage and have been 
positively selected during the development of tumors. The passenger mutations do not confer 
the selective growth advantage and also do not contribute to cancer development
22
. 
The passenger mutations account for the major part of somatic mutations while the 
number of driver mutations is limited. Approximately 140 genes that contain driver mutations 
have been revealed
23,24
. Most tumors contain two to six driver mutations, while the number of 
somatic driver mutations varies among different cancers. Lung cancers have a relatively high 
number of driver mutations while ovarian and breast cancers have less driver mutations
25
. 
Some driver mutations are commonly present among multiple tumor types such as mutations 
in TP53, PI3KCA, and RAS genes. In addition, there are also tumor type-specific somatic 
driver mutations identified. For example, mutations in GATA3 and MAP3K1 are breast 
cancer-specific, whereas KEAP1 mutations are lung cancer-specific
25
. Somatic recurrent 
driver mutations relatively frequently identified in breast cancers are in genes such as AKT1, 
BRCA1, CDH1, CYCLIND1, FGFRs, GATA3, MYC, MAP3K1, HER2, PIK3CA, PTEN, RB1, 
TBX3 and TP53
22,26
. For HER2, GATA3, MYC, PIK3CA and TP53, the frequency of somatic 
mutations is larger than 10% across all breast cancers
27
. Some of these genes are found 
mutated more frequently in specific subtypes of breast cancer. For example, somatic 
mutations in GATA3 have been identified in 14% of ER+ breast cancers while the mutations 
are virtually absent in ER- breast cancers. Furthermore, the TP53 mutation frequency in 
luminal subtype cancers (12% in luminal A subtype and 32% in luminal B subtype) is lower 
compared with the frequency in basal-like (84%) and HER2+ subtype tumors (75%)
27
.  
Catalogues of somatic driver and passenger mutations have been established and have 
provided us more insight into the mutational processes that take place during tumorigenesis
28
. 
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Mutational processes evolve across the lifetime of cancers and cause the somatic mutations 
that arise during the development of tumors. Each process generates classes of mutations and 
these patterns, designated mutational signatures, can be recognized. The mutational 
signatures have illustrated several mutational processes in the mutational catalogs of cancer 
cells
29
. For example, the mutation signatures found in lung and skin tumors match those 
generated by tobacco exposures and ultraviolet light, respectively. Specifically, C:G>A:T 
substitutions are common in smoking-associated lung cancer, whereas CC:GG>TT:AA 
nucleotide substitutions are prevalent in UV light-associated skin cancers
29
. Five distinct 
mutational signatures have been defined in breast cancer named signature 1b, 2, 3, 8 and 13
21
. 
Signature 1b is characterized by the prominence of C>T substitutions at NpCpG 
trinucleotides and shows correlation with age of diagnosis. Signature 2 and 13 are 
characterized by C>T and C>G substitutions in the context of TpCpN nucleotides that are 
attributed to the AID/APOBEC family of cytidine deaminases. APOBEC3B was identified as 
one of the underlying enzymatic sources of these types of mutations in breast cancer
30
. In 
addition, APOBEC1
31
, APOBEC3A
32
 and AOPBEC3H
33
 were also suggested to be involved 
in these mutational signatures. Moreover, this mutational process associates with regional 
somatic hypermutation termed kataegis in breast cancer
21,34,35
. Signature 3 arises as a 
consequence of BRCA1 or BRCA2 deficiency caused by germline mutations or somatic 
inactivation of these genes, which are implicated in homologous-recombination-based DNA 
double-strand break repair. By sequencing a total of 560 whole breast cancer genomes, 
Nik-Zainal et al.
36
 have recently revealed a total of 12 base substitution mutational signatures 
including the five mutational signatures previously observed in breast cancer, but also six 
rearrangement signatures. Base substitution signature 8, which contributes CC>AA double 
nucleotide substitutions, as well as rearrangement signature 3 and 5, appear to be also 
associated with BRCA1 and BRCA2 deficiency
36
.  
 
1.3.2 Hereditary breast cancer 
A family history of breast cancer is a major risk factor for developing breast cancer. Up to 15% 
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of breast cancer patients have at least one first-degree relative with breast cancer. This 
familial clustering of breast cancer suggests a hereditary component of the disease. In 
addition to somatic mutations, hereditary breast cancers are thus also caused by germline 
mutations. Familial breast cancer has been associated with mutations in different 
susceptibility genes, which may be classified as high-, moderate-, and low-risk susceptibility 
genes (Figure 1.2).  
High-risk genes include BRCA1
37
, BRCA2
38
, CDH1
39
, PTEN
40
, STK11
41
, and TP53
42
. The 
two high-risk genes BRCA1 or BRCA2 were discovered in the 1990s and pathogenic 
mutations in BRCA1 or BRCA2 are known to increase the breast cancer risk by 10- to 
20-fold
43
. Mutations in these two high-risk genes are responsible for approximately 25% of 
the familial breast cancer risk. Other high-risk genes (CDH1, PTEN, STK11 and TP53) cause 
5% of the familial breast cancer risk
44
.  
Moderate-risk genes include ATM, CHEK2, NBS1 and RAD50 and mutations in these 
genes confer 2- to 4-fold increased breast cancer risks
45
. PALB2 was originally also identified 
as a moderate-risk gene
46
, but recent evidence suggests that the breast cancer risk conferred 
by PALB2 mutations may be higher. The risk was shown to be eight to nine times as high 
among the PALB2 mutation carriers at the age of 40 and six to eight times as high among 
those at the age of 40 to 60
47,48
. BRIP1, which codes for BRCA1-binding helicase was 
considered as a candidate breast cancer moderate-risk gene49. However, truncating variants in 
BRIP1 were proven to be not associated with breast cancer risk50. Moderate-risk genes 
explain about 5% of the familial breast cancer risk.  
Until now, more than 90 common low-risk alleles have been identified through genome 
wide association studies (GWAS). These alleles are common in the population and display 
low effect sizes (up to 1.3)
51
. The more than 90 identified low-risk susceptibility loci explain 
around 16% of the familial breast cancer risk (Table 1.1) and are scattered throughout the 
genome. Some variants locate near genes with known functions, while others are in 
gene-poor regions. Most of these variants map to non-coding regions of the genome and are 
enriched for FOXA1 and ER binding sites and H3K4me1 epigenome modifications
52
. 
Although the individual risks of these low-risk loci are not very substantial, their combined 
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effects are able to increase breast cancer risk significantly
53
. By stratifying the female 
population using 77 low-risk loci, the top 1% of women would have a 3.36-fold higher breast 
cancer risk than the population in the middle quintile, while the odds ratio for women in the 
highest compared with the middle quintile was 1.82
54
. It has also been observed that some 
low-risk loci significantly modify breast cancer risk in BRCA1 and BRCA2 mutation 
carriers
55
. The addition of modifier loci to risk models will improve risk assessment and 
influence the approach to genetic counseling, prevention and routine care of breast cancer 
patients with a BRCA1 or BRCA2 mutation
55
. Thus, polygenic risk scores can be used to 
stratify breast cancer risk and thereby improve the targeting of breast cancer screening 
programs.  
Taken together, all the high-, moderate-, and low-risk susceptibility genes explain around 
51% of the familial breast cancer. It is estimated that another 1,000 loci may still remain 
unidentified and could contribute an additional 14% of familial breast cancer risk
56
. GWAS 
and genome-wide sequencing projects are needed to continue identifying new breast cancer 
variants. 
 
Figure 1.2 Familial breast cancer risk genes and alleles.  
 
 
 
 
 
16 | P a g e  
 
Table 1.1 Over 90 low-risk breast cancer loci identified from genome-wide association 
studies. 
 
SNP LOCUS GENE OR MAF Study 
rs2981582 10q26 FGFR2 1.26 0.36 Easton, et al.57, 2007  
rs3803662 16q12 TNRC9/LOC643714 1.20 0.25 
rs889312  5q11 MAP3K1 1.13 0.28 
rs13281615 8q24  1.08 0.40 
rs3817198 11p15 LSP1 1.07 0.30 
rs1045485 2q CASP8 0.88 0.13 COX, et al.58, 2007 
rs13387042  2q35 TNP 1.12 0.49 Stacey, et al.59, 2007 
rs10941679 5p12 MRPS30 1.19 0.25 Stacey, et al.60, 2008 
rs4973768 3p24 SLC4A7 1.11 0.47 Ahmed, et al.61, 2009 
rs6504950 17q22 STXBP4 /COX11 0.95 0.28 
rs2046210 6q25 ER 1.29 0.36 Zheng, et al.62, 2009 
rs11249433 1p11  1.16 0.42 Thomas, et al.63, 2009 
rs999737 14q24 RAD51L1 0.94  
rs3757318 6q25 CCDC170 1.30 0.07 Turnbull, et al.64, 2010 
rs1011970  9p21 CDKN2B 1.20 0.16 
rs2380205  10p15  0.94 0.44 
rs614367 11q13  1.15 0.15 
rs10995190 10q21 ZNF365 0.86 0.14 
rs704010 10q22 ZMIZ1 1.07 0.39 
rs8170 19p13 BABAM1 1.26 0.19 Antoniou, et al.65, 2010 
rs2363956 19p13 ANKLE1 0.84 0.51 
rs865686 9q31  0.89 0.37 Fletcher, et al.66, 2011 
rs10069690 5p15  TERT 1.18 0.26 Haimen, et al.67, 2011  
rs10771399 12p11  0.85 0.12 Ghoussaini, et al.68 2012 
rs1292011 12q24  0.92 0.41 
rs2823093 21q21  0.94 0.27 
rs9485372 6q25 TAB2 0.90 0.45 Long, et al.69, 2012 
rs17530068  6q14   1.12 0.18 Siddiq,, et al.70, 2012 
 rs2284378  20q11  RALY 1.08 0.20 
rs616488 1p36 PEX14 0.94 0.33 Michailidou, et al.56, 2013 
 rs11552449  1p13 DCLRE1B  1.08 0.17 
rs4849887 2q14  0.90 0.10 
rs2016394 2q31 METAP1D-DLX1-DLX2 0.95 0.48 
s1550623 2q31 CDCA7 0.91 0.16 
rs16857609 2q35 DIRC3 1.09 0.26 
rs6762644 3p26 ITPR1-EGOT 1.06 0.40 
rs12493607 3p24 TGFBR2 1.04 0.35 
rs9790517 4q24 TET2 1.09 0.23 
rs6828523 4q34 ADAM29 0.89 0.13 
rs10472076 5q11 RAB3C 1.06 0.38 
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rs1353747 5q11 PDE4D 0.90 0.10 
rs1432679 5q33 EBF1 1.06 0.43 
rs11242675 6p25 FOXQ1 0.97 0.39 
rs204247 6p23 RANBP9 1.06 0.43 
rs720475 7q35 ARHGEF5-NOBOX 0.93 0.25 
rs9693444 8p12  1.07 0.32 
rs6472903 8q21 CASC9 0.88 0.18 
rs2943559 8q21 HNF4G 1.17 0.07 
rs11780156 8q24 MIR1208 1.13 0.16 
rs10759243 9q31  1.07 0.39 
rs7072776 10p12 MLLT10-DNAJC1 1.11 0.29 
rs11814448 10p12 DNAJC1 1.35 0.02 
rs7904519 10q25 TCF7L2 1.06 0.46 
rs11199914 10q26  0.94 0.32 
rs3903072 11q13 DKFZp761E198 0.92 0.47 
rs11820646 11q24  0.93 0.41 
rs12422552 12p13  1.11 0.26 
rs17356907 12q22 NTN4 0.89 0.30 
rs11571833 13q13 BRCA2 1.39 0.01 
rs2236007 14q13 PAX9 0.88 0.21 
rs2588809 14q24 RAD51B 1.07 0.16 
rs941764 14q32 CCDC88C 1.05 0.34 
rs17817449 16q12 FTO 0.95 0.40 
rs13329835 16q23 CDYL2 1.14 0.22 
rs527616 18q11  0.91 0.38 
rs1436904 18q11 CHST9 0.93 0.40 
rs4808801 19p13 ELL 0.94 0.35 
rs3760982 19q13 C19orf61-KCNN4-LYPD5-ZNF283 1.06 0.46 
rs132390 22q12 EMID1-RHBDD3-EWSR1 1.36 0.04 
rs6001930 22q13 MKL1 1.17 0.11 
rs554219 11q13  CCND1 1.33 0.12 French, et al.71, 2013  
rs75915166 11q13  CCND1 1.38 0.06 
rs78540526 11q13  CCND1 1.42 0.08 
rs4245739 1q32 MDM4 1.14 0.26 Garcia-Closas, et al.72, 
2013 rs6678914 1q32 LGR6 1.10 0.59 
rs11075995 16q12 FTO 1.11 0.24 
rs12710696 2p24  1.10 0.36 
rs10069690 5p15  1.06 0.26 Bojesen, et al.73, 2013 
rs7726159 5p15 TERT 0.05 0.34 
rs1053338 3p21  ATXN7 1.07 0.13 Milne, et al.74, 2014 
rs6964587 7q21 AKAP9 1.05 0.39 
rs2290203 15q26 PRC1 1.08 0.50 Cai, et al.75, 2014  
rs4951011 1q32 ZC3H11A 1.09 0.28  
rs10474352 5q14 ARRDC3  1.09 0.48 
rs12405132 1q21 NBPF10 0.96 0.36 Michailidou, et al.51, 2015 
rs12048493 1q21  1.04 0.34 
rs72755295 1q43 EXO1 1.19 0.03 
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rs6796502 3p21  0.92 0.09 
rs13162653 5p15  0.92 0.45 
rs2012709 5p13  1.06 0.46 
rs7707921 5q14 ATG10 0.94 0.23 
rs9257408 6p22  1.05 0.38 
rs4593472 7q32 FLJ43663 0.92 0.35 
rs13365225 8p11  0.89 0.17 
rs13267382 8q23 LINC00536 1.07 0.36 
rs11627032 14q32 RIN3 0.94 0.26 
chr17:29230520 17q11 ATAD5 0.94 0.20 
rs745570 17q25  0.94 0.50 
rs6507583 18q12 SETBP1 0.91 0.07 
 
1.4 Clinical outcome of breast cancer  
The types of treatment for breast cancer are surgery, radiation therapy, and systemic therapy, 
which can be administered in the neoadjuvant, adjuvant and recurrent settings. Surgery is 
usually the first step to treat localized breast cancer, which can be preceded by neoadjuvant 
systemic therapy to improve operability and reduce the extent of surgery, and followed by 
adjuvant systemic therapy to aim for cure and reduce the risk of metastases. Hormonal, 
anti-HER2 targeted therapies and chemotherapy are applied as systemic therapy. The decision 
on the type of systemic adjuvant therapy given to a patient is based on many factors. 
According to the 2013
76
 and 2015
77
 St. Gallen guidelines, this decision should be based on 
the intrinsic subtypes of breast cancer (Figure 1.3). Since luminal A and luminal B subtypes 
are ER positive, hormonal therapy should be applied for these subtypes. Whereas tamoxifen 
can be used for premenopausal patients, aromatase inhibitors should be used for postmeno- 
pausal patients
77
. In addition, for patients with luminal A tumors with a large tumor volume 
and patients with luminal B tumors, chemotherapy could be added to hormonal therapy
78
. The 
antibody trastuzumab is an HER2-targetted medication that can also be combined with 
chemotherapy (e.g. taxanes) for patients with HER2+ breast cancer
79-81
. Newer HER2- 
targeting agents (e.g. lapatinib, pertuzumab, T-DM1, neratinib) have been developed in recent 
years that may or may not be combined with trastuzumab
82
. For patients with basal-like and 
normal-like breast cancers, which usually have triple negative phenotypes, chemotherapy 
(anthracyclines and taxanes) is recommended.  
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Following adjuvant treatment, around 40% of all patients with breast cancer suffer a 
recurrence locally, regionally, or at distant metastatic sites. Ten to 20% of all recurrences are 
locoregional, while others are distant metastases
83
. As is the clinical practice in the adjuvant 
setting, treatment of patients with metastatic breast cancer is still based on the phenotype of 
the primary tumor. However, it has been shown that discordance in ER, PR and HER2 status 
between primary and recurrent breast cancer occurs frequently
84,85
. For therapeutic decision 
making, ER, PR, and HER2 status should, if possible, therefore be reevaluated in the 
recurrent tumor(s).  
In order to individualize the treatment of breast cancer, prognostic and predictive 
biomarkers have been studied extensively. Prognostic markers intend to predict aggressive- 
ness of a patient’s tumor independent of treatment, while predictive markers evaluate the 
response of a patient to a specific cancer therapy.  
 
Figure 1.3 The systemic treatment based on the intrinsic subtypes of breast cancer according 
St. Gallen criteria. 
 
 
 
1.4.1 Traditional clinical prognostic and predictive factors 
Tumor stage is a powerful predictor of breast cancer prognosis and the TNM system is the 
most common system used to describe the tumor stage
86
. This system is based on three 
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clinical characteristics: tumor size (T), axillary lymph node status (N) and metastases (M). 
Based on this system, breast cancers are classified into five stages (0-IV), with stage 0 
indicating an excellent prognosis and stage IV a very poor prognosis.  
Tumor grade is a strong prognostic factor and is determined by the Scarff-Bloom- 
Richardson grading system
87
. Grading is derived from an assessment of three morphological 
features: tubule formation, nuclear pleomorphism and mitotic count. Each of these three 
features is scored on a scale of 1-3 and the scores of all three features are added together. 
Based on the final score, breast cancers are classified into three grades. Low grade tumors are 
well differentiated and have a better prognosis than higher grade tumors. The risk of relapse 
at 10 years is around 95% for patients with grade 1 tumors compared with only 40% for grade 
3 tumors
88
. Patients with grade 1 tumors of less than 2cm in size even have an excellent 
prognosis with a 5-year survival of 99%
89,90
.  
 
1.4.2 Traditional molecular prognostic and predictive markers 
ER expression is one of the most important biomarkers in breast cancer since ER is the target 
of endocrine therapies. ER-positive breast cancers are associated with a slower tumor growth, 
lower histological grade and a better overall prognosis. ER currently is the best predictor for 
response to hormonal treatment. Patients with ER-positive disease have benefit from 
aromatase inhibitor or tamoxifen treatment. 
PR is also an important biomarker in breast cancer. The expression of PR is regulated by 
ER and high tumor PR levels are associated with a good prognosis in primary breast cancer. 
Furthermore, high tumor PR levels are associated with a favorable clinical outcome in 
patients with primary and metastatic disease treated with endocrine therapy
91-95
. 
HER2 is overexpressed in 15% of all primary breast cancers. HER2 amplification was 
found to be a strong prognostic maker in primary breast cancer
96,97
. Furthermore, the 
overexpression of HER2 is a strong marker of favorable prognosis for trastuzumab therapy in 
primary breast cancer
98,99
, but a marker of unfavorable prognosis in patients receiving 
endocrine therapy
100
. HER2-targeted therapy prolongs overall survival in HER2+ 
metastatic breast cancer
101,102
.  
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Finally, Ki67 is a nuclear non-histone protein that is associated with cellular proliferation 
and has been shown to be of prognostic value in primary breast cancer
103,104
. Ki67 has also 
been shown to be an important predictive marker of unfavorable outcome for anti-hormonal 
therapy
105
 and chemotherapy
106
 in primary breast cancer and for unfavorable response to 
neoadjuvant chemotherapy in locally advanced breast cancer
107
.  
ER, PR, HER2 and Ki67 are traditional molecular prognostic and predictive markers, but 
many other biomarkers have been identified, including various gene expression signatures
108
.  
 
1.4.2 Prognostic and predictive gene signatures 
Various prognostic gene expression signatures for patients with early breast cancer have been 
reported. A few of the most important signatures are described below. A 70-gene signature 
(MammaPrint) has been developed on a group of 78 patients with node-negative breast 
cancer who did not receive adjuvant chemotherapy and were younger than 55 years
109
. The 
top 70 genes were significantly correlated with clinical outcome and this signature was an 
independent predictor of metastasis-free survival. In addition, a 76-gene signature was 
identified in 286 lymph-node-negative patients who had not received adjuvant systemic 
treatment. This 76-gene profile represented a strong prognostic factor for the development of 
distant metastasis in untreated patients
110,111
 and in patients who received adjuvant tamoxifen 
therapy
112
. A 21-gene recurrence score signature (Oncotype DX) was defined to predict the 
risk of distant recurrence in patients with ER-positive breast cancer who received adjuvant 
tamoxifen therapy
113
. Furthermore, a 97-gene signature has been developed to examine the 
association of gene expression profiles and histologic grade
114
. It discriminates grade 2 
tumors into low and high risk of recurrence subgroups.  
Several predictive gene expression signatures have also been developed to predict the 
patient’s type of response to breast cancer treatment. For example, the 21-gene recurrence 
score was not only able to predict the prognosis in patients who receive adjuvant tamoxifen in 
primary breast cancer, but was also able to predict chemotherapy benefit in node-negative 
ER+ patients
113
. Furthermore, a two-gene expression ratio of HOXB13 and IL17BR was 
identified to have predictive utility
115
. A high HOXB13:IL17BR ratio was associated with a 
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high risk of recurrence and predicted poor outcome on tamoxifen therapy in patients with 
primary breast cancer. The high HOXB13:IL17BR ratio was also associated with poor 
progression-free survival in patients with recurrent breast cancer received tamoxifen first-line 
therapy
116
. In addition, a 44-gene signature has been identified that predicts anti-estrogen 
therapy outcome in ER-positive recurrent breast cancer patients
117
. The 44-gene signature 
predicted a significantly longer progression-free survival time and tamoxifen resistance with 
an accuracy of 80%. Thus, gene expression profiling has been performed to aid clinicians to 
predict prognosis and guide the use of anti-cancer therapy in breast cancer
118,119
.  
Moreover, a mutiprotein signature urokinase plasminogen activator (uPA) and its 
inhibitor, PAI-1 have been shown to be prognostic and predictive biomarkers for breast 
cancer
120
. High levels of uPA/PAI-1 predicted adverse prognosis in breast cancer 
patients
121,122
 and good response to adjuvant chemotherapy in patients with early breast 
cancer
123,124
. 
The continuing identification of relevant predictive and prognostic biomarkers and 
signatures facilitates the promise for individualized treatment. Gene expression profiling has 
been instrumental in this and provided novel predictive and prognostic tools. With respect to 
gaining biological insight, studying all the relevant genes present in large multigene gene 
signatures is less straight forward. With respect to the 2-gene HOXB13:IL17BR ratio this 
should not be problematic and it has become clear that HOXB13 is involved in the 
modulation of ER signaling pathways
125
, which supports its clinical correlation with 
tamoxifen resistance.  
 
1.5 Summary 
Breast cancer is the most common cancer in women worldwide and incidence rates vary 
widely. Similar to countries with high incidence, rates have been rising in countries with 
lower rates as well in recent years. Many factors such as age, gender, life style, family history 
of breast cancer and estrogen exposure are associated with breast cancer. Importantly, breast 
cancer is a genetic disease that arises from somatic and/or germline mutations. Familial breast 
cancer has been associated with mutations in three different risk classes of susceptibility 
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genes/alleles, which account for approximately 51% of familial breast cancer risk. To explain 
the remaining 49% of familial breast cancer risk, larger GWAS and genome-wide sequencing 
projects need to be performed to identify new breast cancer genes/variants. Furthermore, 
human breast cancer is a heterogeneous disease and can be classified into various molecular 
subtypes. The different subtypes associate with different clinical outcomes. Breast cancer is 
the pioneer of treatment individualization. ER, PR and HER2 status as well as the intrinsic 
tumor subtypes have been used for many years to select appropriate systemic therapy. In 
recent years, additional molecular signatures such as Oncotype DX, MammaPrint and the 
HOXB13:IL17BR ratio have been developed to improve the prediction of prognosis and guide 
the use of anti-cancer therapy in breast cancer.  
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Chapter 2 
Aims and outline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
38 | P a g e  
 
  
39 | P a g e  
 
Aims and outline of this thesis 
Breast cancer is one of the most common malignancies and has a serious impact on female 
health. Fortunately, great progress has been achieved in the survival of breast cancer patients 
in recent years mostly due to earlier detection and more effective treatment regimens. To 
facilitate early detection of breast cancer, we need to be able to identify those individuals at 
significant risk for developing breast cancer at an early stage. Until now, several familial 
breast cancer susceptibility genes/alleles have been identified, which account for 51% of 
familial breast cancer risk. Novel breast cancer susceptibility genes/variants need to be 
identified to explain the remaining 49% of familial breast cancer risk. In addition, to further 
improve current anti-cancer treatment that patients undergo, we need knowledge to give the 
right drug to the right patient to achieve individualized or personalized treatment. To further 
improve the survival of breast cancer patients, it is thus important to identify novel genetic 
variants/factors associated with breast cancer risk, therapy response and aggressiveness that 
can be used to guide treatment decision making.  
  
The aims of this thesis are focused on two main topics: 
1. The discovery of novel genetic variants that predict an increased risk to develop breast 
cancer (Chapter 3 and 4). 
2. The discovery of novel genetic markers that predict the prognosis of breast cancer 
patients and their response to therapy (Chapter 5 and 6). 
 
In Chapter 3, we evaluated whether the p.G84E mutation or other mutations in the HOXB13 
gene are associated with an increased breast cancer risk. The HOXB13 p.G84E mutation was 
reported to be a prostate cancer susceptibility allele
1
. HOXB13 plays an important role in 
breast tumor progression. Moreover, a high ratio of HOXB13:IL17BR expression is of 
prognostic and predictive value for ER-positive breast cancer patients
2,3
. Based on these 
observations, we hypothesized that HOXB13 might also be a breast cancer susceptibility gene. 
So far, three studies had investigated the association between p.G84E and breast cancer risk, 
but obtained contradictory results
4-6
. We analyzed the entire coding region of the HOXB13 
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gene in 1,250 Dutch familial breast cancer cases and 800 geographically matched controls. 
Then two recurrent mutations were genotyped in 4,520 non-BRCA1/2 cases and 3,127 
controls to evaluate the association between the mutations and breast cancer risk.   
Mutations in the NBS1 gene have been reported to be associated with risks for several 
cancer types including breast cancer
7
. The functional variant rs2735383 locates to the 3’UTR 
of NBS1. The rs2735383CC variant could influence the binding ability of several microRNAs, 
thereby decreasing the expression level of the NBS1 gene. Rs2735383 had been associated 
with an increased risk of lung cancer and colorectal cancer
8,9
. In this respect, the aim of the 
Chapter 4 was to investigate whether NBS1 rs2735383 was also associated with breast 
cancer risk. We analyzed NBS1 rs2735383 in the Rotterdam Breast Cancer Study (RBCS) and 
in 45 studies of the Breast Cancer Association Consortium (BCAC) through imputation. Then 
we evaluated the association of NBS1 rs2735383 with breast cancer risk in the overall and 
subgroup analyses. 
APOBEC3B mRNA overexpression was associated with a hypermutator phenotype and 
poor outcomes in ER-positive breast cancer patients
10
. The 29.5 kb APOBEC3B deletion 
polymorphism results in a hypermutator phenotype
11
 and has been associated with breast 
cancer risk. In Chapter 5, we investigated whether the 29.5 kb APOBEC3B deletion 
polymorphism associates with clinical outcome of breast cancer. Copy number analysis was 
performed by quantitative PCR in primary tumors of 1,756 Dutch breast cancer patients. The 
prognostic and predictive value of the APOBEC3B 29.5 kb deletion polymorphism was 
analyzed in four different clinical cohorts. As increased APOBEC3B mRNA levels had 
prognostic value and were associated with a poor prognosis in ER-positive breast cancer 
patients
10
, we further evaluated the relation between APOBEC3B copy number and 
APOBEC3B mRNA expression. 
Mutations in GATA3 are frequently identified (i.e. larger than 10% of cases) among 
breast cancers
12
. GATA3 mutations have been reported to be associated with ER-positive 
breast cancer
13
 and the response to neoadjuvant aromatase inhibitor treatment
14
. Therefore, 
we aimed in Chapter 6 to investigate whether GATA3 mutations predicted the outcome of 
tamoxifen treatment in the advanced setting. We analyzed mutations in exons 5 and 6 of the 
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GATA3 gene in 235 ER-positive primary breast cancers and evaluated the association of the 
mutations with clinical outcome of patients who received tamoxifen as first-line therapy for 
recurrent disease. We also performed GATA3 mRNA expression analysis in 148 out of the 
235 tumors to evaluate the association of GATA3 mRNA expression with clinical outcome of 
first-line tamoxifen therapy.  
Finally, the results of Chapter 3-6 are discussed in Chapter 7 and are summarized in 
Chapter 8. 
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Abstract 
The HOXB13 p.G84E mutation has been firmly established as a prostate cancer susceptibility 
allele. Although HOXB13 also plays a role in breast tumor progression, the association of 
HOXB13 p.G84E with breast cancer risk is less evident. Therefore, we comprehensively 
interrogated the entire HOXB13 coding sequence for mutations in 1,250 non-BRCA1/2 
familial breast cancer cases and 800 controls. We identified two predicted deleterious 
missense mutations, p.G84E and p.R217C, that were recurrent among breast cancer cases and 
further evaluated their association with breast cancer risk in a larger study. Taken together, 
4,520 familial non-BRCA1/2 breast cancer cases and 3,127 controls were genotyped including 
the cases and controls of the whole gene screen. The concordance rate for the genotyping 
assays compared with Sanger sequencing was 100%. The prostate cancer risk allele p.G84E 
was identified in 18 (0.56%) of 3,187 cases and 16 (0.70%) of 2,300 controls (OR=0.81, 95% 
CI=0.41-1.59, P=0.54). Additionally, p.R217C was identified in 10 (0.31%) of 3,208 cases 
and 2 (0.087%) of 2,288 controls (OR=3.57, 95% CI=0.76-33.57, P=0.14). These results 
imply that none of the recurrent HOXB13 mutations in the Dutch population are associated 
with breast cancer risk, although it may be worthwhile to evaluate p.R217C in a larger study. 
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Introduction 
Breast cancer is the second leading cause of cancer death in Western countries and the most 
frequently diagnosed cancer in Western women. A family history of breast cancer is a major 
risk factor for developing breast cancer. Approximately 10-15% of breast cancer patients have 
at least one first-degree relative with breast cancer. Depending on the number of affected 
first-degree relatives, this implies risk ratios for breast cancer of 1.80 for one affected relative 
to 3.90 for three or more affected relatives
1
. 
  Familial breast cancer has been associated with mutations in several high- and 
moderate-risk breast cancer susceptibility genes, as well as an increasing number of low-risk 
breast cancer susceptibility alleles. The two high-risk genes BRCA1 and BRCA2 were 
identified in the 1990s and germline mutations in these genes confer average cumulative 
lifetime breast cancer risks by age 70 of 65% and 45%, respectively
2-4
. Mutations in 
moderate-risk genes ATM, CHEK2, PALB2, and RAD50 confer 2- to 4-fold increased breast 
cancer risks
5
, although recent evidence suggests that the breast cancer risk conferred by 
PALB2 mutations may be higher than initially thought
6,7
. The more than 90 identified 
common low-risk alleles, on the other hand, display small effect sizes (i.e. per allele odds 
ratios) of up to 1.3
8
. However, taken together in a polygenic risk score (PRS; calculated from 
77 SNPs) the lifetime risk of breast cancer for women in the highest quantile of this PRS was 
17%
9
. In total, these breast cancer susceptibility genes and alleles account for approximately 
35% of the familial breast cancer risk, which means that the underlying cause of the majority 
of the familial breast cancer risk thus still remains unexplained. 
In this respect, the rare variant c.251G>A (p.G84E; rs138213197) in the HOXB13 gene 
was reported to be associated with prostate cancer
10
. Meta-analyses have estimated the 
increased prostate cancer risk from this mutation to be 4- to 5-fold and even higher among 
early onset prostate cancer patients and prostate cancer patients with a family history of 
prostate cancer
11-14
. Moreover, fine-scale mapping at the HOXB gene cluster at 17q21-22 had 
identified a number of highly correlated common SNPs that were associated with prostate 
cancer risk and tagging the rare HOXB13 p.G84E variant. This not only further established 
the association between HOXB13 p.G84E and prostate cancer risk, but also provided 
47 | P a g e  
 
evidence that GWAS associations could actually be driven by rare variants
15
. Interestingly, 
the HOXB13 gene encodes a transcription factor that plays an important regulatory role 
during embryonic development, but also in tumorigenesis. For example, HOXB13 was 
reported to regulate the transcription of androgen receptor (AR) target genes
16
 and together 
with HOXA9, HOXB13 is the most commonly deregulated gene in solid cancers
17
. Moreover, 
HOXB13 was shown to preferentially bind a low-risk prostate cancer susceptibility allele 
located in an AR and FOXA1 binding site (i.e. rs339331), thereby enhancing RFX6 
expression and promoting metastasis
18
. 
In breast cancer, HOXB13 gene expression is regulated by estrogen in an ER dependent 
manner
19
. Furthermore, a high HOXB13:IL17BR expression ratio was found to be a 
prognostic and predictive biomarker for ER-positive breast cancer patients
20,21
. The poor 
response to tamoxifen therapy that is predicted from high HOXB13 expression has been 
shown to be mediated by HOXB13 through the direct suppression of ER, the induction of IL6 
expression and mTOR pathway activation
22
. Considering these observations, HOXB13 might 
also be a likely candidate for being a breast cancer susceptibility gene. So far, three studies 
have investigated this hypothesis but obtained contradictory results. In the study by Alanee et 
al.
23
, the HOXB13 p.G84E mutation was shown to confer an increased breast cancer risk, 
however, Akbari et al. could not replicate this association in a larger study
24
. Laitinen et al. 
also found no association with breast cancer risk, but did observe a suggestive association in 
a particular high-risk subgroup
25
. Importantly, all three studies only investigated the prostate 
cancer risk-associated variant p.G84E. 
In this study, we therefore analyzed the entire coding region of the HOXB13 gene in 
1,250 Dutch familial breast cancer cases and 800 geographically matched controls to 
establish whether the p.G84E mutation or other mutations in the HOXB13 gene are associated 
with an increased breast cancer risk.  
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Methods 
Study population 
The samples included in this study were from two Dutch breast cancer case-control studies: 
RBCS and ABCS-F. RBCS cases (N=2,751) were selected from the database of the Clinical 
Genetics Centre at Erasmus University Medical Centre in Rotterdam, representing the 
Southwestern part of the Netherlands. Selected families included all families counselled 
between 1994 and 2014 that presented with at least two cases of female breast cancer or at 
least one case of female breast cancer and one case of ovarian cancer in first- or 
second-degree relatives. At least one of these two cases needed to be diagnosed before the 
age of 60. For each family, the youngest breast cancer patient who had been tested for BRCA1 
and BRCA2 was assigned to be the index case and included in RBCS. Additionally, breast 
cancer cases were included that were diagnosed either before 40 years with unilateral breast 
cancer or before 50 years with bilateral breast cancer without having a first or second degree 
relative diagnosed with either breast or ovarian cancer. All cases and their tested relatives 
were negative for both BRCA1 and BRCA2 mutations. Median age of the RBCS cases was 44 
years (range 18-92 years). The RBCS control population (N=1,159) was geographically 
matched and included women from cystic fibrosis families who were either spouses of 
individuals at risk of being carrier of a CFTR mutation or individuals who were tested 
negative for a CFTR mutation and were counselled between 1996 and 2010. Median age of 
the RBCS controls was 41 years (range 10-97 years).   
ABCS-F cases (N=1,769) were selected from the linked databases of the Division of 
Diagnostic Oncology and the Tumor Registry of the Antoni van Leeuwenhoek hospital in 
Amsterdam
26
. We included female breast cancer patients of all ages (median age was 42 years 
(range 14-79 years)), without a pathogenic BRCA1/2 mutation or unclassified variant, who 
were counselled in the Family Cancer Clinic and diagnosed and/or treated with cancer in the 
Antoni van Leeuwenhoek hospital in the period 1995-2012. For each family, only the 
youngest breast cancer patient who had been tested for BRCA1 and BRCA2 was included. 
ABCS-F controls (N=1,968) are healthy women of all ages (median age was 49 years (range 
49 | P a g e  
 
18-69 years)) from the general population and were recruited through the blood bank.  
All experiments were performed in accordance with the Code of Conduct of the 
Federation of Medical Scientific Societies in the Netherlands (http://www.fmwv.nl). The RBCS 
and ABCS-F studies were approved by the Medical Ethical Committes of the Erasmus 
Medical Center Rotterdam and the Netherlands Cancer Institute, respectively. All individuals 
gave written informed consent.  
 
PCR and Sanger sequencing  
The entire HOXB13 (RefSeq NM_006361.5) coding region was analyzed for sequence 
variations in 1,250 non-BRCA1/2 familial breast cancer cases and 800 controls from RBCS 
(i.e. indexes from families counselled between 1995 and 2009 for cases and between 1996 
and 2006 for controls) using PCR and Sanger sequencing. Twenty nanograms of DNA, 
extracted from peripheral blood, was PCR amplified in a final volume of 15µl containing 1X 
GoTaq buffer (Promega, Madison, WI), 1.5mM MgCl2, 200µM dNTPs (GE Healthcare, 
Waukesha, WI), 1µM of each primer and 0.75U of GoTaq polymerase (Promega) using an 
ABI2720 thermal cycler (Thermo Scientific, Waltham, MA). First, the PCR reaction was 
incubated for 5 minutes at 94ºC, followed by 35 cycles of 94ºC for 30 seconds, 58ºC for 1 
minute and 72ºC for 1 minute. The PCR reaction ended with a final extension at 72ºC for 5 
minutes. Removal of dNTPs and primers before sequencing was done by ExoSAP-IT PCR 
Product Cleanup (Affymetrix, Santa Clara, CA). Briefly, 2.5µl of PCR product was incubated 
with 0.5µl of ExoSAP-IT and 1x GoTaq buffer in a final volume of 12.5µl. Incubation took 
place in an ABI2720 thermal cycler for 15 minutes at 37ºC. Then enzymes were inactivated at 
80ºC for 15 minutes before proceeding with Sanger sequencing. The sequencing reaction 
contained 2µl of ExoSAP-it treated PCR product, 1µl BigDye Terminator v3.1 reaction mix 
(Thermo Scientific), 1X BigDye Terminator sequencing buffer (Thermo Scientific) and 
0.16µM of sequencing primer in a final volume of 10µl and was carried out in an ABI2720 
thermal cycler according to the following protocol: 1 cycle of 96ºC for 2 minutes and 25 
cycles of 96ºC for 30 seconds, 58ºC for 30 seconds and 72ºC for 2 minutes. Subsequently, the 
sequencing product was precipitated with absolute ethanol and 3M of NaAc, resuspended in 
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20µl of Hi-Di formamide (Thermo Scientific), and ran on an ABI3130XL Genetic Analyzer 
(Thermo Scientific). Sequencing electropherograms were analyzed using Mutation Surveyor 
v3.20 software (Softgenetics, State College, PA). Sanger sequencing was successful for  
96.2% of the samples and PCR and sequencing primer sequences for the two exons of the 
HOXB13 gene are available in Supplementary Table 3.1.   
 
Taqman genotyping 
Genotyping of the c.251G>A (p.G84E; rs138213197) and c.649C>T (p.R217C; rs139475791) 
mutations in the HOXB13 gene was performed for all 7,647 DNA samples from RBCS and 
ABCS-F using custom-made Taqman genotyping assays (Thermo Scientific) on a Mx3000/ 
3005P qPCR machine (Agilent Technologies, Santa Clara, CA). For genotyping p.G84E, 
0.5X of Taqman genotyping assay and 0.5X of Taqman Genotyping Master Mix (Thermo 
Scientific) was added to 20ng of genomic DNA in a final volume of 10µl, whereas for 
p.R217C, 1X Taqman genotyping assay and 1X ABsolute qPCR Mix, low ROX (Thermo 
Scientific) was added to 20ng of genomic DNA in a final volume of 10µl. Cycling conditions 
were: 1 cycle of 10 minutes (for Taqman Genotyping Master Mix) or 15 minutes (for 
ABsolute qPCR Mix, low ROX) at 95ºC and 45 cycles of 15 seconds at 92ºC and 1 minute at 
60ºC. The MxPro qPCR software v4.10 (Agilent) was used to visualize the genotyping results. 
The call rate of the genotyping assays was 97.9% for p.G84E and 98.1% for p.R217C, 
respectively, and Taqman assay design is specified in Supplementary Table 3.2. The accuracy 
of both genotyping assays was evaluated by comparing genotypes obtained from the 1,250 
RBCS cases and 800 RBCS controls through Taqman genotyping with genotypes obtained 
from Sanger sequencing. For quality control, each 96-well plate included a wild-type and a 
heterozygous sample. Samples that were identified to be positive by either Sanger sequencing 
or in Taqman assays were independently confirmed by Sanger sequencing. 
 
Statistical analyses 
The association of both HOXB13 mutations (i.e. p.G84E and p.R217C) with breast cancer 
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risk was evaluated by comparing the carrier allele frequency between cases and controls 
using either a χ2 test or a Fisher’s exact test (i.e. when the expected frequency ≤5 in any of 
the groups). Odds ratios and their 95% confidence intervals were calculated based on 2×2 
table analysis of the cases and controls. All statistical tests were two-sided and P-values were 
considered statistically significant when smaller than 0.05.  
 
Results 
HOXB13 whole gene screen 
We evaluated the entire coding sequence of the HOXB13 gene for germline mutations in 
1,250 non-BRCA1/2 breast cancer patients and 800 controls from the Rotterdam Breast 
Cancer Study (RBCS) study. Using PCR and Sanger sequencing, we identified a total of 
eleven different rare variants (Table 3.1) and two more common variants (c.366C>T; p.S122S; 
rs8556; minor allele frequency (MAF) cases=0.126; MAF controls=0.138 and c.513T>C; 
p.S171S; rs9900627; MAF cases=0.079; MAF controls=0.091). Seven of the eleven rare 
variants were missense variants and five of these were present either in only one case or one 
control. The other two missense variants (i.e. c.251G>A and c.649C>T) were detected in 
multiple cases and controls (Figure 3.1). The c.251G>A (p.G84E) mutation was detected in 4 
of 1,215 (0.33%) cases and 6 of 759 (0.79%) controls, whereas the c.649C>T mutation was 
detected in 6 of 1,206 (0.50%) cases and 1 of 765 (0.13%) controls (Table 3.1). For all 
identified missense variants the carrier frequency was low, resulting in insufficient power to 
draw meaningful statistical inferences from this sample size. However, it did appear that the 
prostate cancer risk variant p.G84E was less prevalent in breast cancer cases than controls, 
whereas the prevalence of the p.R217C variant appeared to be higher in breast cancer cases 
compared with controls. Interestingly, both missense mutations were predicted to be 
deleterious based on three different prediction classification tools: PredictSNP
27
 (i.e. 87% for 
p.G84E and p.R217C), Meta-SNP
28
 (i.e. 0.730 for p.G84E and 0.895 for p.R217C) and 
PON-P2
29
 (i.e. 0.967 for p.G84E and 0.974 for p.R217C). Moreover, p.G84E is localized in 
the MEIS binding domain, whereas p.R217C is localized to the homeodomain of HOXB13, 
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further increasing the likelihood that these mutations are pathogenic
10
. For these reasons, we 
decided to further pursue these two variants in a second sample set by expanding RBCS (i.e. 
to all indexes from families counselled between 1994 and 2014 for cases and between 1996 
and 2010 for controls) and by including the Amsterdam Breast Cancer Study (ABCS-F).  
 
Table 3.1 Rare variants identified by PCR and Sanger sequencing of the HOXB13 gene. 
 
    Carrier allele frequency 
Position 
Nucleotide 
change 
Amino acid 
change Rs number Controls Cases 
5'UTR c.1-6G>A   0/759 (0%) 1/1215 (0.08%) 
Exon 1 c.251G>A p.G84E rs138213197 6/759 (0.79%) 4/1215 (0.33%) 
Exon 1 c.328C>G p.P110A  0/759 (0%) 1/1215 (0.08%) 
Exon 1 c.330C>A p.P110P rs33993185 1/759 (0.13%) 0/1215 (0%) 
Exon 1 c.332C>T p.A111V  0/759 (0%) 1/1215 (0.08%) 
Exon 1 c.569C>T p.P190L  0/759 (0%) 1/1215 (0.08%) 
Intron 1 c.601+49G>A  rs200606700 0/759 (0%) 1/1215 (0.08%) 
Exon 2 c.649C>T p.R217C rs139475791  1/765 (0.13%) 6/1206 (0.50%) 
Exon 2 c.803G>A p.R268Q   0/765 (0%) 1/1206 (0.08%) 
Exon 2 c.832G>T p.V278L rs200997384 1/765 (0.13%) 0/1206 (0%) 
3'UTR  c.855+28C>A   3/765 (0.39%) 5/1206 (0.41%) 
 
Genotyping HOXB13 p.G84E and p.R217C 
In order to facilitate fast and accurate screening of the p.G84E and p.R217C mutations, two 
custom-designed Taqman genotyping assays were developed for analyzing all samples from 
the RBCS and ABCS-F case-control studies. In total, all 4,520 non-BRCA1/2 breast cancer 
patients and 3,127 controls were genotyped. These also included the 1,250 non-BRCA1/2 
breast cancer patients and 800 controls from the RBCS study that were used in the whole 
gene screen to evaluate the quality of the genotyping assay. The concordance between the 
results from the custom-designed Taqman genotyping assay and Sanger sequencing of these 
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patients was 100%. Interestingly, the p.G84E mutation was identified in 18 (0.56%) of 3,187 
cases and 16 (0.70%) of 2,300 controls (Table 3.2). Consistent with the results from the 
whole gene screen, the p.G84E mutation was more prevalent in controls than cases, however, 
this was not statistically significant (OR=0.81, 95% CI=0.41-1.59, P=0.54). The p.R217C 
mutation was identified in 10 (0.31%) of 3,208 cases and 2 (0.087%) of 2,288 controls (Table 
3.2). Consistent with the results of the whole gene screen, the p.R217C mutation was more 
prevalent in cases than in controls, but this difference was not significant (OR=3.57, 95% 
CI=0.76-33.57, P=0.14). These results imply that none of the recurrent HOXB13 mutations in 
the Dutch population are associated with breast cancer risk. 
 
Figure 3.1 Identification of the c.251G>A (p.G84E) and c.649C>T (p.R217C) mutations. 
 
 
 
The lower electropherograms show the c.251C>A (left) and the c.649C>T (right) mutations which are indicated 
with an asterisk as compared with the wild-type sequences in the top panels. 
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Table 3.2 Association of HOXB13 p.G84E and p.R217C with breast cancer risk. 
 
Variant Study 
Carrier allele frequency 
OR (95% CI) P-value Controls Cases 
c.251G>A / p.G84E RBCS  3/356 (0.84%) 9/1,465 (0.61%)   
 ABCS-F 13/1,944 (0.67%)  9/1,722 (0.52%)   
 Combined 16/2,300(0.70%) 18/3,187 (0.56%) 0.81 (0.41-1.59) 0.54 
c.649C>T / p.R217C RBCS  0/355 (0%) 5/1,473 (0.34%)   
 ABCS-F  2/1,933 (0.10%)  5/1,735 (0.29%)   
 Combined  2/2,288 (0.087%) 10/3,208 (0.31%) 3.57 (0.76-33.57) 0.14 
 
OR: odds ratio, CI: confidence interval. 
 
Discussion 
The HOXB13 c.251G>A (p.G84E) mutation has been shown to confer a 4- to 5-fold increased 
prostate cancer risk
11-13
. In this study, we have explored whether HOXB13 gene mutations are 
also associated with breast cancer risk. Our results show that the prostate cancer risk variant 
p.G84E is not associated with breast cancer risk. Furthermore, another recurrent mutation in 
the HOXB13 gene (i.e. c.649C>T; p.R217C) was also not associated with increased breast 
cancer risk, although it was more prevalent in cases than controls. 
Interestingly, Alanee et al. had previously shown that the HOXB13 p.G84E mutation 
conferred a moderate to high breast cancer risk
23
. The mutation was found in 6 (0.7%) of 877 
familial, mostly Caucasian, non-BRCA1/2 breast cancer cases, while the frequency in controls 
was 0.1% (OR=5.7, 95% CI=1.0-40.7, P=0.02). However, in a larger study (i.e. 4,037 cases 
of which 1,082 familial and 2,762 controls) conducted by Akbari et al., no association of the 
p.G84E mutation with breast cancer risk was observed among Canadian and Polish women of 
European origin
24
. The mutation was identified in 7 (0.17%) of 4,037 cases and 4 (0.14%) of 
2,762 controls (OR=1.2, 95% CI=0.3-4.1, P=1.0). Also a third study by Laitinen et al. 
consisting of 986 cases (i.e. of which 323 familial non-BRCA1/2 and 663 unselected) and 
1,449 controls found no overall association between the p.G84E mutation and (familial) 
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breast cancer risk among Finnish women
25
. However, the authors did observe a suggestive 
association in a specific high-risk familial subgroup (i.e. 86 cases from the Pirkanmaa area of 
Finland; OR=3.2, 95% CI=0.9-11.9). Here in this study, we also did not observe an increased 
breast cancer risk associated with the p.G84E mutation in a relatively large study of 3,270 
familial non-BRCA1/2 breast cancer cases and 2,327 controls (OR=0.81, 95% CI=0.41-1.59, 
P=0.54). It thus appears that the HOXB13 p.G84E mutation is not associated with increased 
breast cancer risk, although it cannot be excluded that it is associated with a specific high-risk 
subgroup. Considering the low population frequency, much larger studies are needed to 
determine whether the latter is indeed the case.  
The whole gene screen for HOXB13 also identified c.649C>T (p.R217C) as a recurrent 
mutation in the Dutch population, which was predicted to be pathogenic. In both the 
discovery as well as the validation phase of the study, the mutation was more prevalent in 
familial breast cases than controls, but the association with breast cancer risk was not 
significant. Considering the wide CIs and the very low population frequency, there is a 
chance that the study was underpowered and failed to detect the association. Evaluation of 
HOXB13 p.R217C in a larger study or a population with a higher carrier allele frequency 
might therefore still be worthwhile to pursue. Since the p.G84E variant varies widely among 
different geographic populations (i.e. highest in North and West-Europeans and lowest in 
non-Europeans)
30,31
, this may also be the case for p.R217C. Interestingly, the p.R217C 
mutation had been described before among a few prostate cancer cases
30,32
, however, Xu et al. 
reported that p.R217C did not co-segregate with prostate cancer in the two families they 
identified
30
. Unfortunately, we were not able to perform informative segregation analysis in 
the present study as for only two families we had DNA available for two additional family 
members. In addition, we identified too little carriers of the mutation to say anything relevant 
regarding an excess of prostate cancer in their families as compared with non-carrier cases.  
To conclude, none of the recurrent HOXB13 mutations that we identified in the Dutch 
population were associated with breast cancer risk, although it may be worthwhile to evaluate 
p.R217C in a larger study or a population with a higher allele frequency. 
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Abstract 
NBS1, also known as NBN, plays an important role in maintaining genomic stability. 
Interestingly, rs2735383 G>C, located in a microRNA binding site in the 3’-untranslated 
region (UTR) of NBS1, was shown to be associated with increased susceptibility to lung and 
colorectal cancer. However, the relation between rs2735383 and susceptibility to breast 
cancer is not yet clear. Therefore, we genotyped rs2735383 in 1,170 familial non-BRCA1/2 
breast cancer cases and 1,077 controls using PCR-based restriction fragment length 
polymorphism (RFLP-PCR) analysis, but found no association between rs2735383CC and 
breast cancer risk (OR=1.214, 95% CI=0.936-1.574, P=0.144). Because we could not exclude 
a small effect size due to a limited sample size, we further analyzed imputed rs2735383 
genotypes (r
2
>0.999) of 47,640 breast cancer cases and 46,656 controls from the Breast 
Cancer Association Consortium (BCAC). However, rs2735383CC was not associated with 
overall breast cancer risk in European (OR=1.014, 95% CI=0.969-1.060, P=0.556) nor in 
Asian women (OR=0.998, 95% CI=0.905-1.100, P=0.961). Subgroup analyses by age, age at 
menarche, age at menopause, menopausal status, number of pregnancies, breast feeding, 
family history and receptor status also did not reveal a significant association. This study 
therefore does not support the involvement of the genotype at NBS1 rs2735383 in breast 
cancer susceptibility.    
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Introduction  
The DNA damage response (DDR) pathway maintains the stability of the human genome via 
a complex network of pathways integrating signal transduction, regulation of the cell cycle 
and repair of DNA. Double-strand breaks (DSBs), a particularly severe form of DNA damage, 
arise as a consequence of cell replication, programmed DNA rearrangements (i.e. meiosis and 
VDJ recombination) and exposure to carcinogens. When left unrepaired, DSBs may cause 
genomic instability, cell death and cancer
1,2
. In fact, mutations in genes involved in DSB 
repair, but also in the DDR pathway in general, are involved in the etiology of many human 
cancers. The two major repair pathways that mediate the repair of DSBs are the 
template-mediated homologous recombination repair pathway and the more error-prone 
non-homologous end-joining pathway
3,4
. The MRE11/RAD50/NBS1 complex is an important 
regulator of DSB repair through these pathways as this complex not only acts as a sensor of 
DSBs, but also recruits and activates the ATM protein to the break and activates it
5
. Activation 
of ATM, the central mediator of response to DSBs, initiates a cascade of signaling pathways 
involved in cell cycle checkpoint control, DNA repair and, when necessary, apoptosis by 
phosphorylation of p53, CHEK2, BRCA1, FANCD2 and NBS1 amongst others
6
. 
The DDR plays an important role in susceptibility to breast cancer. In fact, all of the 
currently identified high- and moderate-risk breast cancer genes (i.e. BRCA1, BRCA2, 
CHEK2, ATM, NBS1 and PALB2) are involved in DNA repair
7,8
. As the majority of familial 
breast cancer risk is not yet attributable to known risk genes, this makes other genes encoding 
proteins involved in the DDR pathway attractive candidates for breast cancer susceptibility 
genes. The recent identification of the early DNA damage response gene MCPH1 as a novel 
breast cancer susceptibility gene illustrates that this hypothesis still holds
9
.   
In this respect, the NBS1 gene is located at chromosome 8q21 and bi-allelic germline 
mutations in NBS1 cause the chromosomal instability syndrome Nijmegen breakage 
syndrome
10
. In addition, heterozygous carriers of NBS1 mutations are at an increased risk to 
develop several types of cancer
11
. The NBS1 c.657del5 founder mutation is the most prevalent 
mutation implicated in Nijmegen breakage syndrome (i.e. 90%) and has its origin in the 
Slavic population
12
. The mutation confers an overall 2.5- to 3-fold increased cancer risk and is 
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associated with increased risk for breast cancer, prostate cancer and lymphoma specifically
13
. 
Two other NBS1 mutations implicated in Nijmegen breakage syndrome are p.I171V and 
p.R215W. Although both mutations associate with an overall cancer risk of 4-fold and 2-fold, 
respectively, there does not seem to be an increased risk to develop breast cancer 
specifically
13
. 
Besides the rare Nijmegen breakage syndrome-associated mutations, two common 
variants in NBS1 (i.e. p.E185Q; rs1805794 and c.2265+541G>C; rs2735383) have also been 
reported to be associated with risks for several cancer types. Recent meta-analyses for NBS1 
rs1805794 have, however, shown that this variant does not associate with breast cancer 
risk
13-16
, while associations with lung cancer and urinary system cancer are still 
inconclusive
13,16-18
. The functional variant rs2735383, localized in the 3’UTR of NBS1, has 
been shown to modulate the binding ability of microRNA-629 in lung cancer cells and 
microRNA-509-5p in colorectal cancer cells, affect NBS1 transcriptional activity and decrease 
NBS1 mRNA and NBS1 protein levels
19,20
. Although rs2735383 has been associated with an 
increased risk of lung cancer and colorectal cancer
13,20
, its association with breast cancer risk 
is yet unclear. For this reason, we assessed whether NBS1 rs2735383 is associated with breast 
cancer risk in the Rotterdam Breast Cancer Study (RBCS) by RFLP-PCR and in 45 studies of 
BCAC through imputation of the iCOGS array
21
. 
 
Materials and Methods 
Study population 
RBCS cases (N=1,269) came from the database of the Clinical Genetics Department at 
Erasmus University Medical Centre in Rotterdam, representing the Southwestern part of the 
Netherlands. First, we selected families that presented with at least two cases of female breast 
cancer or at least one case of female breast cancer and one case of ovarian cancer in first- or 
second-degree relatives. In addition, at least one of these two cases needed to be diagnosed 
before the age of 60. For each selected family, the youngest breast cancer patient who had 
been tested for BRCA1 and BRCA2 was then assigned to be the index case and included in 
RBCS. Furthermore, breast cancer cases were also included if they were diagnosed either 
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before the age of 40 years with unilateral breast cancer or before 50 years of age with 
bilateral breast cancer and did not report a family history of either breast or ovarian cancer in 
a first or second degree relative. All index cases and their tested relatives did not carry a 
BRCA1 or BRCA2 mutation. The median age of the RBCS cases was 44 years (range 18-92 
years). RBCS controls (N=1,159) came from the same database and geographic location as 
the RBCS cases and included women from cystic fibrosis families who were either spouses of 
individuals at risk of being carrier of a CFTR mutation or individuals who were tested 
negative for a CFTR mutation. The median age of the RBCS controls was 41 years (range 
10-97 years).   
BCAC consists of case-control studies of unrelated women
21
. For the purpose of the 
current analyses, only studies with participants of European and Asian ancestry were included, 
resulting in a total of 45 case-control studies (Supplementary Table S4.3). Studies with 
participants of African ancestry (i.e. two studies) were not included because power in the 
analyses would be low due to a relatively low MAF (i.e. 0.123) and small amount of cases (i.e. 
1,046). Each study was approved by its relevant governing research ethics committee and all 
study participants provided written informed consent. The experimental protocol was 
approved by the Medical Ethical Committee of the Erasmus Medical Center Rotterdam and 
the study was carried out in accordance with the Code of Conduct of the Federation of 
Medical Scientific Societies in the Netherlands (http://www.fmwv.nl). Following genotyping 
on the iCOGS array
21
, quality control exclusions (described below), and analysis-specific 
exclusions, data from the following women were available for analysis: 47,640 patients with 
invasive breast cancer and 46,656 controls, totaling 94,296 BCAC participants.  
 
PCR-based RFLP analysis  
A 324bp fragment of the 3’UTR of NBS1 including rs2735383 was amplified in a duplex 
PCR reaction together with a 713bp fragment of the LRRC4 gene. Primers for NBS1 and 
LRRC4 were present in the PCR reaction at a final concentration of 0.25 and 1µM, 
respectively, and sequences are available in Supplementary Table S4.4. The amplified LRRC4 
fragment served as an internal digestion control and generated two fragments of 549 and 
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164bp upon complete digestion with ScfI (New England Biolabs, Frankfurt am Main, 
Germany). The 324bp amplified NBS1 fragment was only digested when the major G allele 
was present at rs2735383, thereby generating two fragments of 233 and 91bp. Thus upon 
successful digestion with ScfI, samples with rs2735383GG generated four fragments, 
samples with rs2735383GC generated five fragments and samples with rs2735383CC 
generated three fragments (Figure 4.1).    
 
iCOGS genotyping and imputation 
Genotyping of BCAC studies was performed previously using the custom iCOGS Illumina 
Infinium iSelect BeadChip
21
. Briefly, DNA samples from 114,255 BCAC participants were 
genotyped, along with HapMap2 DNAs for European, African, and Asian populations. Raw 
intensity data files underwent centralized genotype calling and quality control
21
. The 
HapMap2 samples were used to identify women with predicted European and Asian ancestry 
by performing  principal component (PC) analysis using a set of over 37,000 unlinked 
markers
22
. Nine European PCs and two Asian PCs were found to control adequately for 
residual population stratification in BCAC data. Samples with a low conversion rate, extreme 
heterozygosity, non-female sex, or one of a first-degree relative pair were excluded. Variants 
were excluded if they were monomorphic or had a call rate <95% (i.e. when MAF>0.05) or 
<99% (i.e. when MAF<0.05), deviation from HWE (i.e. P<10-7), or >2% duplicate 
discordance. 
Imputation of genotypes was performed using 1000 Genomes Project data (v3 April 2012 
release) as the reference panel
23,24
. To improve computation efficiency we used a two-step 
procedure which involved pre-phasing by chromosome and by chunk using SHAPEIT 
software in the first step
25
 and imputation of the phased data using IMPUTE version 2 
software in the second
26
. NBS1 rs2735383 was imputed with an imputation r
2 
> 0.999 in both 
Europeans and Asians.  
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Figure 4.1. Microchip electrophoresis of the RFLP-PCR products of 23 RBCS cases. 
  
 
 
After PCR amplification of NBS1 and LRRC4 fragments (i.e. 324 and 713bp), digestion with SfcI generated four 
fragments (i.e. 549, 233, 164 and 91bp) for samples with rs2735383 GG genotypes, five fragments (i.e. 549, 324, 
233, 164 and 91bp) for samples with rs2735383 GC genotypes and three fragments (i.e. 549, 324 and 164bp) for 
samples with rs2735383 CC genotypes. UM, upper marker; LM, lower marker. 
 
Statistical analyses 
The association between NBS1 rs2735383 and invasive breast cancer risk was evaluated by 
logistic regression analysis providing ORs and 95% CIs. In the analyses of BCAC studies, 
ORs were adjusted for study, age, and PCs. In the analyses of RBCS, ethnicity was not a 
confounding factor thus reported ORs were unadjusted for PCs. For the European and Asian 
BCAC studies, we additionally performed the study-specific logistic regression analysis 
adjusting for age and PCs, and pooled the log ORs in a fixed-effects meta-analysis. Subgroup 
analyses within the European BCAC studies were based on age (i.e. ≤ 50 years and >50 years), 
age at menarche (i.e. ≤13 years and >13 years), age at menopause (i.e. ≤50 years and >50 
years), menopausal status (i.e. premenopausal and postmenopausal), number of full-term 
pregnancies (i.e. ≤ 2 and >2), breast feeding (i.e. no and yes), first-degree family history of 
breast cancer and receptor status (i.e. ER positive, ER negative and triple negative). Clinical 
and demographic characteristics of the BCAC cases are presented in Supplementary Table 
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S4.5. Association between NBS1 rs2735383 and the clinical and demographic characteristics 
were evaluated using a χ2 test. All P-values were two-sided and P<0.05 was considered to be 
statistically significant after correction for multiple testing by the Bonferroni procedure. 
Logistic regression analyses were performed using SPSS statistics version 23 (IBM 
Corporation, Armonk, NY) and fixed-effects meta-analyses using Stata version 13 (StataCorp, 
College Station, TX).  
 
Results 
To evaluate the association between NBS1 rs2735383 and breast cancer risk, we analyzed 
NBS1 rs2735383 by RFLP-PCR in 1,269 non-BRCA1/2 familial breast cancer patients and 
1,159 controls from RBCS. Since genetic risk factors are usually enriched in familial/ 
early-onset breast cancer cases, specifically selecting these breast cancer patients improves 
statistical power. Among the cases, 516 had the GG genotype, 507 had the GC genotype and 
147 had the CC genotype at rs2735383 (minor allele frequency (MAF)=0.342). Among the 
controls, 462 had the GG genotype, 501 had the GC genotype and 114 had the CC genotype 
(MAF=0.338). For both cases and controls, the genotypes of rs2735383 were in Hardy- 
Weinberg equilibrium (HWE). Because rs2735383 CC was associated with an increased risk 
of lung cancer and colorectal cancer under a recessive genetic model
13,20
, we analyzed the 
association of rs2735383 with breast cancer in a similar way. However, rs2735383 was not 
significantly associated with the risk of breast cancer (OR=1.214, 95% CI=0.936-1.574, 
P=0.144; Table 4.1). In this respect, the lung cancer risk conferred by the rs2735383 CC 
genotype had been associated with an OR of 1.28 (95% CI=1.21-1.46, P<0.001), whereas the 
colorectal cancer risk had been associated with an OR of 1.55 (95% CI=1.27-1.94, P< 
10
-4
)
13,20
. Here, we do not observe a similar effect size for breast cancer as for lung and 
colorectal cancer. However, RBCS is underpowered to detect effect sizes smaller than those 
observed for lung cancer (i.e. OR<1.28). Therefore, we cannot exclude rs2735383 CC is 
associated with breast cancer, but confers a smaller risk.  
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Table 4.1 Association of NBS1 rs2735383 with breast cancer risk in the RBCS study. 
 
Genetic model N Controls N Cases OR (95% CI) P-value 
Recessive     
     GG + GC 963 1023 1  
     CC 114 147 1.214 (0.936-1.574) 0.144 
 1077 1170   
 
N, number of; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval. 
 
Table 4.2 Association of NBS1 rs2735383 with overall breast cancer risk in the European and 
Asian BCAC studies. 
 
Ethnicity Genetic model 
N  
Controls 
N  
Cases 
MAF 
Controls 
MAF 
Cases OR (95% CI)* P-value* 
European  40,0042 41,915 33.44% 33.39%   
 Recessive     1.014 (0.969-1.060) 0.556 
 Dominant     1.006 (0.978-1.035) 0.684 
 Additive     1.000 (0.979-1.021) 0.984 
Asian  6,614 5,725 40.71% 40.58%   
 Recessive     0.998 (0.905-1.100) 0.961 
 Dominant     0.995 (0.922-1.074) 0.900 
 Additive     0.997 (0.946-1.050) 0.911 
 
N, number of; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval. 
* adjusted for age, study and principal components (PCs). In the European analyses nine PCs were added to the 
regression model and in the Asian analyses two PCs.  
 
For this reason we analyzed NBS1 rs2735383 in BCAC studies through imputation. Since 
we had data available for RBCS on rs2735383 from both the PCR-based RFLP and from 
imputation, we first evaluated the concordance between the two methods. In total, from 1,313 
samples (i.e. 646 cases and 667 controls) we had genotypes for rs2738353 available from 
both RFLP-PCR and imputation. Importantly, the agreement between the two methods was 
97.1% (i.e. concordance in 1,275 of 1,313 samples, r
2
=0.933) and was similar among cases 
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and controls (i.e. 98.1% versus 96.1%). Moreover, case-control ORs for imputed data were 
comparable to ORs obtained by RFLP-PCR (OR=1.14, 95% CI=0.80-1.62 versus OR=1.17, 
95% CI=0.83-1.66). Therefore, we used the imputed data on rs2735383 to evaluate further its 
association with breast cancer risk.  
For the overall analysis in Europeans we had 41,915 cases and 40,042 controls available 
from 36 case-control studies. However, rs2735383 was not associated with breast cancer risk 
in Europeans, neither under a recessive genetic model (OR=1.014, 95% CI=0.969-1.060, 
P=0.556; Table 4.2 and Figure 4.2), nor under a dominant (OR=1.006, 95% CI=0.978-1.035, 
P=0.684; Table 4.2) or additive model (per allele OR=1.000, 95% CI=0.979-1.021, P=0.984; 
Table 4.2). Because the association with increased lung and colorectal cancer risk was 
observed in the Asian population
13,20
, we also performed the same analysis in the nine Asian 
BCAC studies. In total, we had 5,725 cases and 6,614 controls available for this analysis 
from nine case-control studies. Also in Asians we did not find any association between 
rs2735383 and breast cancer risk for either the recessive (OR=0.998, 95% CI=0.905-1.100, 
P=0.961; Table 4.2 and Figure 4.2), dominant (OR=0.995, 95% CI=0.922-1.074, P=0.900; 
Table 4.2) or additive genetic model (per allele OR=0.997, 95% CI=0.946-1.050, P=0.911; 
Table 4.2). These results imply that NBS1 rs2735383 is not associated with an increased risk 
to develop invasive breast cancer.    
A previous study had shown that rs2735383 may be associated with breast cancer risk in 
women >50 years, women with age at menarche >13 years, women with premenopausal 
status, women with number of abortions ≤2 and women who have breast fed, but not by age 
at menopause, number of pregnancies and family history
27
. Therefore, to exclude that an 
association of rs2735383 with breast cancer risk exists in a particular subgroup of individuals 
or breast cancer patients, we performed subgroup analysis according to age, age at menarche, 
age at menopause, menopausal status, number of full-term pregnancies, breast feeding, family 
history and receptor status. We did, however, not find any association between the genotype 
at rs2735383 and the risk of breast cancer in any of these subgroups for the recessive genetic 
model (Table 4.3). Also for the dominant and additive genetic models we found no 
association between the genotype at rs2735383 and breast cancer risk that would withstand 
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multiple testing correction (Supplementary Tables S4.1 and S4.2). NBS1 rs2735383 is thus 
not associated with the risk for breast cancer, either in the overall analyses or in specific 
subgroups.  
 
Figure 4.2 Forest plots for the association between rs2735383 and breast cancer risk. 
 
 
 
A) for the 36 European BCAC studies and B) for the nine Asian BCAC studies. Study-specific (squares) were 
from a recessive genetic model and adjusted by age and PCs. Overall or pooled ORs (diamonds) were from a 
fixed-effects meta-analysis. 
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Table 4.3 Subgroup analysis of NBS1 rs2735383 and breast cancer risk in the European 
BCAC studies. 
 
Subgroup 
N  
Controls 
N  
Cases 
MAF 
Controls 
MAF 
Cases OR (95% CI)* P-value* 
Age       
     ≤ 50 years 13,055 13,362 33.76% 33.41% 0.977 (0.899-1.062) 0.581 
     > 50 years 26,987 28,553 33.28% 33.38% 1.026 (0.971-1.084) 0.356 
Age at menarche       
     ≤ 13 years      14,312 13,843 33.72% 33.13% 0.984 (0.914-1.060) 0.677 
     > 13 years 8,964 8,095 32.65% 33.63% 1.077 (0.978-1.187) 0.131 
Age at menopause       
     ≤ 50 years 5,571 7,288 32,79% 33.43% 1.019 (0.906-1.146) 0.755 
     > 50 years 3,366 4,262 33.50% 33.24% 0.993 (0.855-1.154) 0.926 
Menopausal status       
     Premenopausal 8,974 7,412 33.66% 33.07% 0.981 (0.887-1.085) 0.715 
     Postmenopausal 19,648 17,353 33.39% 33.56% 1.007 (0.943-1.075) 0.844 
Number of full-term 
pregnancies       
     ≤ 2 21,008 19,722 33.53% 33.20% 1.004 (0.942-1.071) 0.893 
     > 2 8,258 7,327 33.26% 33.44% 1.032 (0.931-1.144) 0.549 
Breast feeding       
     No 6,849 6,805 33.36% 33.25% 0.988 (0.884-1.104) 0.828 
     Yes 11,947 12,709 33.68% 33.28% 0.978 (0.903-1.060) 0.594 
Family history       
     1
st
 degree relative    
     with BC 23,648 4,119 33.21% 32.68% 0.990 (0.884-1.108) 0.859 
Receptor status       
     ER positive 39,699 25,959 33.47% 33.40% 1.021 (0.970-1.075) 0.427 
     ER negative 39,618 6,774 33.42% 32.90% 0.991 (0.908-1.082) 0.846 
     Triple negative 30,696 2,712 33.10% 32.04% 0.980 (0.847-1.134) 0.788 
 
N, number; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; ER, estrogen receptor; BC, 
breast cancer 
*recessive genetic model adjusted for age, study and nine principal components. 
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Discussion  
The CC genotype of the common variant rs2735383 in the 3’UTR of NBS1 has been shown to 
be associated with an increased cancer risk, specifically for lung and colorectal cancer (lung 
cancer: OR=1.28, 95% CI=1.21-1.46, P<0.001 and colorectal cancer: OR=1.55, 95% CI= 
1.27-1.94, P<10
-4
)
13,20
. In the current study, we evaluated the association of NBS1 rs2735383 
with breast cancer risk. We found that the CC genotype of rs2735383 did not confer an 
increased breast cancer risk, neither in the overall analyses nor in the subgroup analyses.   
In agreement with these results, a small study by Han et al. consisting of 239 
premenopausal breast cancer patients and 477 matched controls from the Nurses’ Health 
Study II showed that rs2735383 did not associate with breast cancer risk under an additive 
genetic model (OR=0.92, 95% CI=0.72-1.16, P=0.469)
28
. Moreover, the study of Wu et al. 
consisting of 450 breast cancer patients and 450 cancer-free controls from the Henan Province 
in China also found no association with overall breast cancer risk
27
. However, after 
stratification according to reproductive factors, rs2735383 CC was found to be associated 
with an increased breast cancer risk for women >50 years, women with age at menarche >13 
years, women with premenopausal status, women with number of abortions ≤2 and women 
who have breast fed, but not by age at menopause, number of pregnancies and family 
history
27
. In the current study we therefore also performed subgroup analysis by age, age at 
menarche, age at menopause, menopausal status, number of full-term pregnancies, breast 
feeding, family history and receptor status, but did not find any association between 
rs2735383 and risk of breast cancer in any of these subgroups that would withstand multiple 
testing correction. We thus could not replicate the earlier positive findings in women >50 
years, women with age at menarche >13 years, premenopausal women and women who have 
breast fed. A possible, but not very likely, explanation for the difference in outcome between 
the studies may be the European versus Asian ethnicity. In the current study we chose to 
perform the subgroup analysis only in the European studies and not the Asian studies as this 
made sure that we had sufficient power in the subgroup analysis to identify smaller effects of 
rs2735383 on breast cancer risk. In this respect, a more plausible explanation would be that 
subgroup analyses, especially in a small study population (i.e. 450 cases and 450 controls in 
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the study of Wu et al.), could have easily given rise to false positive findings. Therefore, one 
should be careful when reporting positive findings from multiple small subgroup comparisons 
and always use appropriate levels of statistical significance
29
. Unfortunately, in the study from 
Wu et al., there is no mention of multiple testing correction. 
It was found that the rs2735383CC genotype significantly decreased the expression of the 
NBS1 gene through either binding of microRNA-629 to the 3’UTR of NBS1 gene in lung 
cancer cells or the binding of microRNA-509-5p to the 3’UTR of NBS1 gene in colorectal 
cancer cells
19,20
. Since low expression of NBS1 may reduce the efficiency of DSB repair, this 
way the rs2735383CC genotype likely confers an increased lung and colorectal cancer risk. 
According to our study, however, the rs2735383CC genotype does not confer an increased 
breast cancer risk. Considering that in lung and colorectal cancer cells different microRNAs 
appear to be downregulating NBS1 expression, tissue specific expression of these microRNAs 
may likely play a role. Besides microRNA-509 and microRNA-629, the C allele at rs2735383 
has also been predicted to enhance the binding of microRNA-499 and microRNA-508 to the 
3’UTR of NBS1
27
. However, if these microRNAs are not expressed in normal breast tissue, 
the CC genotype of rs2735383 will not associate with breast cancer risk as NBS1 cannot be 
downregulated by any of these microRNAs. At least in breast cancer cells, none of these 
microRNAs, except microRNA-629, are expressed at substantial levels (source: TCGA 
Research Network; http://cancergenome.nih.gov/). Since microRNAs are often deregulated 
between normal tissue and cancer tissue, this does not necessarily represent the situation in 
normal breast cells. Thus, further evaluation of the miRNA expression levels in normal (breast) 
tissue, but also their correlation with the genotype at rs2735383 should provide more insight 
for the tissue specificity of rs2735383 and cancer risk. 
Importantly, in contrast to lung and colorectal cancer susceptibility, the results of this 
study do not support the presence of an association (i.e. OR>1.04 for Europeans and OR> 
1.11 for Asians) between the genotype at rs2735383 in the 3’UTR of NBS1 and breast cancer 
susceptibility. 
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Abstract 
Increased APOBEC3B mRNA levels are associated with a hypermutator phenotype and poor 
prognosis in ER-positive breast cancer patients. In addition, a 29.5 kb deletion polymorphism 
of APOBEC3B, resulting in an APOBEC3A-B hybrid transcript, has been associated with an 
increased breast cancer risk and the hypermutator phenotype. Here we evaluated whether the 
APOBEC3B deletion polymorphism also associates with clinical outcome of breast cancer. 
Copy number analysis was performed by quantitative PCR (qPCR) in primary tumors of 
1,756 Dutch breast cancer patients. The APOBEC3B deletion was found in 187 patients of 
whom 16 carried a two-copy deletion and 171 carried a one-copy deletion. The prognostic 
value of the APOBEC3B deletion for the natural course of the disease was evaluated among 
1,076 lymph-node negative (LNN) patients who did not receive adjuvant systemic treatment. 
No association was found between APOBEC3B copy number values and the length of 
metastasis-free survival (MFS; hazard ratio (HR)=1.00, 95% confidence interval (CI)=0.90- 
1.11, P=0.96). Subgroup analysis by ER status also did not reveal an association between 
APOBEC3B copy number values and the length of MFS. The predictive value of the 
APOBEC3B deletion was assessed among 329 ER-positive breast cancer patients who 
received tamoxifen as the first-line therapy for recurrent disease and 226 breast cancer 
patients who received first-line chemotherapy for recurrent disease. No association between 
APOBEC3B copy number values and the overall response rate (ORR) to either tamoxifen 
(odds ratio (OR)=0.88, 95% CI=0.69-1.13, P=0.31) or chemotherapy (OR=0.97, 95% CI= 
0.71-1.33, P=0.87) was found. Thus, in contrast to APOBEC3B mRNA levels, the 
APOBEC3B deletion polymorphism has neither a prognostic nor a predictive value for breast 
cancer patients. Although a correlation exists between APOBEC3B copy number and mRNA 
expression, it is relatively weak. This suggests that other mechanisms exist that may affect 
and therefore determine the prognostic value of APOBEC3B mRNA levels. 
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Introduction 
Breast cancer, like most cancer types, is a heterogeneous disease. The heterogeneous nature 
of breast cancer, however, provides challenges for identifying appropriate markers for disease 
susceptibility and progression, as well as treatment selection. Accordingly, transcriptional 
profiling has identified five molecular subtypes of breast cancer, which differ in prognosis, 
efficacy of treatment and preferred site of metastasis
1-5
. More recently, the catalogues of 
mutations across human cancers have provided us insight into the mutational processes that 
drive tumorigenesis
6,7
. For breast cancer, five distinct mutational signatures have been 
defined that contribute in varying degree to the final mutational catalogue of a breast tumor
7
. 
One of the most pronounced mutational processes impacting breast tumorigenesis is driven 
by the AID/APOBEC family of cytidine deaminases and gives rise to C>T and C>G 
substitutions at TpCpN nucleotides. Moreover, this mutational process associates with 
regional somatic hypermutation or kataegis
6-8
.  
The APOBEC3 gene cluster is located on chromosome 22q13.1-q13.2 and harbors seven 
APOBEC3 genes that have evolved in primates (i.e. APOBEC3A, APOBEC3B, APOBEC3C, 
APOBEC3D, APOBEC3F, APOBEC3G and APOBEC3H)
9
. APOBEC3s play a role in 
intracellular defense through restriction of retroviral infections, but also of infections from the 
cancer-associated hepatitis B virus, the human papilloma virus and human T-lymphotropic 
virus
10
. Moreover, APOBEC3A, APOBEC3B, APOBEC3C and APOBEC3F are also able to 
inhibit LINE1 retrotransposition
11,12
. Besides its role in innate immunity, APOBEC3B has 
recently been identified as an endogenous source of mutation in breast cancer
13
. APOBEC3B 
mRNA expression was found to be upregulated in most breast cancers and tumors expressing 
high levels of APOBEC3B had a 2-fold increase in mutations compared with tumors 
expressing low APOBEC3B levels. This suggests that APOBEC3B, at least in part, underlies 
the APOBEC-driven mutational process in breast cancer, but also in other cancers
13,14
. In line 
with these findings, high levels of APOBEC3B mRNA were associated with a shorter 
disease-free survival in ER-positive, LNN, systemically untreated patients, as well as with 
earlier recurrence in luminal subtype patients and with a more aggressive phenotype in 
Japanese breast cancers
15-17
. Moreover, APOBEC3B expression has been reported to be 
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associated with a strong enrichment of mitotic and cell cycle-related genes
16
. 
A 29.5 kb germline deletion between the fifth exon of APOBEC3A and the eighth exon of 
APOBEC3B has been identified that essentially removes the complete APOBEC3B coding 
region from the genome and generates a fusion transcript of APOBEC3A with the 3’  
untranslated region (UTR) of APOBEC3B
18
. With a worldwide frequency of 22.5%, the 
frequency of the germline APOBEC3B deletion variant varies widely among the different 
ethnic groups, ranging from being rare in African and European populations (i.e. 0.9% and 
6%, respectively) to being common in Asian and American populations (i.e. 36.9% and 57.7%, 
respectively)
18
. Through a genome-wide association study of copy number variation, Long  
et al. found that the APOBEC3B deletion variant was associated with an increased risk to 
develop breast cancer in Chinese women
19
. This finding was replicated among European
20
 
and Southeast Iranian women
21
, but not among Swedish women
22
. Interestingly, carriers of 
the APOBEC3B deletion were shown to have a greater APOBEC3A mRNA stability resulting 
in higher APOBEC3A levels, increased activity of APOBEC-driven mutational processes and 
more severe DNA damage
23,24
. However, the APOBEC3B deletion polymorphism was not 
associated with the survival of breast cancer patients
16,22
. Thus, despite that APOBEC3B 
overexpression and the APOBEC3B deletion variant both result in a hypermutation phenotype, 
there seems to be a difference between the two mechanisms and their association with clinical 
outcome.  
To investigate the relation between the APOBEC3B deletion polymorphism and clinical 
outcome of 1,756 Dutch breast cancer patients, we explored four different clinical cohorts: 
LNN patients who did not receive any adjuvant treatment, lymph node positive (LNP) 
patients who did receive adjuvant systemic treatment, hormone-naive ER-positive patients 
who received tamoxifen as first-line therapy for recurrent disease and patients that received 
first-line chemotherapy for recurrent disease. Furthermore, to investigate the relation between 
the clinical outcomes based on the APOBEC3B deletion polymorphism versus APOBEC3B 
overexpression, we investigated the correlation between APOBEC3B copy number and 
APOBEC3B mRNA expression.  
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Materials and Methods 
Study population 
The retrospective study cohort consisted of 1,756 breast cancer patients who underwent 
surgery for an invasive primary breast cancer between 1978 and 2001. Inclusion criteria were 
no neoadjuvant treatment, no experience of a previous other cancer (except for basal cell 
carcinoma or stage Ia/Ib cervical cancer), a minimum of 100mg of freshly frozen primary 
tumor tissue available for downstream DNA isolation and DNA available from tissue with a 
tumor cell nuclei percentage ≥30%. Cytosolic ER and PR levels were determined by ligand 
binding assay or enzyme immunoassay
25,26
. ER and/or PR positivity was defined by ≥10 
fmol/mg cytosolic protein and ERBB2 overexpression was defined by a reverse transcriptase 
qPCR expression level ≥ 18
27
. In total, 796 patients underwent breast-conserving 
lumpectomy and 960 patients underwent modified radical mastectomy. In addition, 215 
patients received adjuvant hormonal therapy, 308 patients received adjuvant chemotherapy 
and 6 patients received both adjuvant hormonal therapy and chemotherapy. There were 1,713 
M0 patients and 43 M1 patients. The median age at the time of the primary surgery was 54 
years, while the median age at the start of first-line treatment was 55 years. The 
clinicopathological variables of the patients are shown in Table 5.1. 
The total study cohort consists of four specific studies that were grouped together: 1) 
1,076 LNN patients who did not receive any adjuvant systemic treatment, 2) 528 LNP 
patients who received adjuvant systemic treatment, 3) 329 hormone-naive ER-positive 
patients who received first-line tamoxifen therapy for recurrent disease and 4) 226 patients 
who received first-line chemotherapy for recurrent disease as detailed in Figure 5.1. We 
included all eligible patients fulfilling the study criteria and the general inclusion criteria 
specified above. As a consequence 403 patients were included in two studies (i.e. one study in 
the adjuvant setting and one study in the advanced setting). The total study population, 
however, cannot be considered a consecutive series, since systemically treated LNN patients 
are missing. The total study population, however, cannot be considered a pure consecutive 
series, since systemically treated LNN patients were not included. The reason for this is that 
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we especially wished to study the association of APOBEC3B copy number with the natural 
course of the disease in LNN patients, not potentially confounded by adjuvant systemic 
therapy. 
 
Figure 5.1 Schematic overview of study cohort.  
 
 
 
In total, this retrospective study consists of 1,756 primary breast cancers from patients who underwent surgery 
between 1978 and 2001. Inclusion criteria are specified in the Materials and Methods section. In the adjuvant 
setting, there were 1,076 lymph node negative (LNN) patients who did not receive adjuvant systemic treatment 
and 528 lymph node positive (LNP) patients who received adjuvant systemic treatment for the analysis of MFS. 
In the advanced setting, a group of 329 hormone-naive patients with ER-positive breast cancer received first-line 
tamoxifen for recurrent disease. Of these, 145 patients came from the LNN patients group and 73 came from the 
LNP patients group. The remaining 111 patients in this group did not qualify for MFS analysis (i.e. 82 patients 
did not fulfill LNN or LNP study eligibility criteria and 29 patients already presented with metastasis at the time 
of diagnosis). Furthermore, a group of 226 patients received first-line chemotherapy for recurrent disease. Of 
these, 85 patients came from the LNN patients group and 100 came from the LNP patients group. The remaining 
41 patients in this group did not qualify for MFS analysis (i.e. 27 patients did not fulfill LNN or LNP study 
eligibility criteria and 14 patients already presented with metastasis at the time of diagnosis). 
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Table 5.1 Association of APOBEC3B copy number status with clinicopathological variables 
in 1,756 primary breast cancers. 
 
Variables Deleted Balanced  Amplified P-value 
Total number 187  1260  309   
Age (in years)       0.54 
    ≤40 23 (12.3%) 160 (12.7%) 48     (15.5%)  
    41-55 82 (43.9%) 498 (39.5%) 116   (37.5%)  
    56-70 62 (33.2%) 412    (32.7%) 99     (32.0%)  
    >70 20 (10.7%) 190    (15.1%) 46     (14.9%)  
Menopausal status       0.31 
    Premenopausal 89 (47.6%) 554    (44.0%) 149    (48.2%)  
    Postmenopausal 98 (52.4%) 706    (56.0%) 160    (51.8%)  
Tumor size       1.00 
    pT1 71 (38.0%) 469 (37.2%) 115 (37.2%)  
    pT2 + Unknown 96 (51.3%) 661 (52.5%) 163 (52.8%)  
    pT3 + pT4 20 (10.7%) 130 (10.3%) 31 (10.0%)  
Nodal status       0.041 
    N0   117 (63.6%) 793 (63.5%) 173 (56.5%)  
    N1-3 23 (12.5%) 212 (17.0%) 67 (21.9%)  
    N>3 44 (23.9%) 244 (19.5%) 66 (21.6%)  
Tumor grade       0.052 
    Good/Moderate 34 (23.8%) 193 (21.9%) 66 (29.6%)  
    Poor 109 (76.2%) 689 (78.1%) 157 (70.4%)  
Tumor histology       0.29 
    IDC 129 (83.2%) 833 (80.6%) 196 (78.4%)  
    ILC 10 (6.5%) 119 (11.5%) 30 (12.0%)  
    Other 16 (10.3%) 82 (7.9%) 24 (9.6%)  
ER status       0.24 
    Positive 130 (70.3%) 951 (75.8%) 226 (73.9%)  
    Negative 55 (29.7%) 303 (24.2%) 80 (26.1%)  
PR status       0.99 
    Positive 114 (65.5%) 779 (65.8%) 187 (65.6%)  
    Negative 60 (34.5%) 404 (34.2%) 98 (34.4%)  
HER2 status       0.59 
    Positive 18 (12.6%) 150 (15.7%) 39 (16.2%)  
    Negative 125 (87.4%) 807 (84.3%) 201 (83.8%)  
Adjuvant systemic therapy        0.17 
    None 133 (73.5%) 856 (69.9%) 191 (63.0%)  
    Chemotherapy 26 (14.4%) 219 (17.9%) 63 (20.8%)  
    Hormonal therapy 22 (12.2%) 146 (11.9%) 47 (15.5%)  
    Both 0 (0%) 4 (0.3%) 2 (0.7%)  
 
Note: For nodal status, tumor grade, tumor histology, ER, PR and HER2 status and adjuvant systemic therapy 
the number of patients do not add up to 1,756 because there were missing values for these variables. In addition, 
for the adjuvant systemic treatment variable: some patients were not eligible for adjuvant treatment because they 
were had distant metastasis at the time of primary tumor diagnosis. 
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Routine postsurgical follow-up and the definition of time to metastasis for LNN and LNP 
patients were as described previously
28
. The median follow-up for the 1,604 LNN and LNP 
patients included in the prognostic studies for the analysis of metastasis-free survival (MFS) 
was 114 months (range 10-354 months). Of these 1,604 patients, 686 (42.8%) had developed 
a distant metastasis and 691 (43.1%) of the 1,604 patients died during follow up. More 
specifically, 602 (37.5%) patients died after disease recurrence, whereas 89 (5.5%) patients 
died without evidence of disease recurrence at last follow-up. These 89 patients were 
censored at the date of last follow-up in the analysis of MFS. 
Criteria for follow up and response to tamoxifen therapy were defined by standard 
International Union Against Cancer (Geneva, Switzerland) criteria of tumor response
29
. 
Complete and partial remission (together objective response) was observed in 11 and 48 
patients, respectively, whereas 79 patients had progressive disease. From the patients with 
stable disease, 171 had no change for >6 months, whereas 20 patients had no change for ≤6 
months. According to the advice of the European Organization for Research and Treatment of 
Cancer
30
, we defined overall response as complete and partial remission including stable 
disease >6 months. As a result, 230 patients were classified as responders to tamoxifen and 
99 patients showed no response to tamoxifen. The median follow up of patients after start of 
tamoxifen therapy was 49 months (range: 4-176 months). At the end of the follow up, 304 
(92.4%) patients had developed tumor progression and were counted as events in the analysis 
of progression-free survival (PFS) and 264 patients had died.  
Criteria for follow up and response to chemotherapy were similar to those for tamoxifen 
therapy with the exception that not all patients were chemotherapy-naive. In fact, 45 out of 
226 patients had received adjuvant chemotherapy. Of those, 33 patients received 
cyclophosphamide/methotrexate/5-fluorouracil (CMF), 11 patients received anthracycline- 
based chemotherapy and 1 patient received both. Complete and partial remission was 
observed in 12 and 69 patients, respectively, whereas 66 patients had progressive disease. 
From the 77 patients with stable disease, 54 had no change for >6 courses, whereas 23 
patients had no change for ≤6 courses. We defined overall response as complete and partial 
remission including stable disease >6 courses. As a result, 135 patients were classified as 
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responders to chemotherapy and 89 patients showed no response to chemotherapy. For two 
patients the type of response was ambiguous. The median follow up of patients after start of 
chemotherapy was 30 months (range: 4-153 months). Fifty-two patients received 
consolidation therapy after chemotherapy and PFS was right censored at two months after the 
start of consolidation therapy. At this time point, 138 patients had developed tumor 
progression and were counted as events in the analysis of PFS. At the end of follow up, 210 
patients had died.  
This study was approved by the Medical Ethical Committee of the Erasmus Medical 
Center Rotterdam, the Netherlands (MEC 02.953). As this is a retrospective study using 
remaining material from surgical resection of the patient’s primary tumor, obtaining informed 
consent from the patient was not required provided patient records were anonymized and 
de-identified prior to analysis. Herewith, we adhered to the Code of Conduct of the 
Federation of Medical Scientific Societies in the Netherlands (http://www.fmwv.nl). Results 
are reported in accordance with the REMARK criteria on clinical reporting
31
. 
 
Copy number analysis 
Copy number analysis for APOBEC3B was performed on genomic DNA isolated from 
fresh-frozen primary tumor sections by qPCR on a Mx3000/3005P machine (Agilent 
Technologies, Santa Clara, CA). Briefly, genomic DNA was isolated from two to ten 30µm 
cryostat sections (5-20mg) with the NucleoSpin Tissue kit (Macherey-Nagel, Düren, 
Germany) according the protocol provided by the manufacturer. DNA quantity and quality 
was assessed by Nanodrop and the Quant-iT PicoGreen dsDNA HS Assay Kit (Thermo 
Scientific, Waltham, MA). Next, 0.5X Taqman Copy Number Assay for the APOBEC3B gene 
(Hs04504055_cn; Thermo Scientific), 0.5X Taqman Copy Number Reference Assay (i.e. for 
the RNase P gene; Thermo Scientific) and 0.5X ABsolute qPCR Mix, low ROX (Thermo 
Scientific) were added to 20ng of genomic DNA in a final volume of 17µl. Cycling 
conditions were: 1 cycle of 15 minutes at 95ºC and 45 cycles of 15 seconds at 92ºC and 1 
minute at 60ºC. The MxPro qPCR software v4.10 (Agilent) was used to calculate the cycle 
threshold (Ct) values. Relative quantification analysis was performed within the CopyCaller 
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v2.0 software (Thermo Scientific). For this, the ∆Ct value was calculated for each sample by 
subtracting the Ct value for the target gene (i.e. APOBEC3B) from the Ct value of the 
reference gene (i.e. RNase P). In the case of no Ct value for APOBEC3B after 45 cycles, 
while the RNase P gene was successfully amplified within 32 cycles for that sample, the ∆Ct 
value could not be quantified and the sample was designated to have a two-copy deletion of 
the APOBEC3B gene. For samples where the ∆Ct was quantified, ∆Ct values were converted 
to calculated copy number values by the CopyCaller software as detailed in S5.1Fig. Then, 
samples with calculated copy numbers ≤0.2 were called as two-copy deletion of the 
APOBEC3B gene, samples with calculated copy numbers >0.20 and ≤1.41 as one-copy 
deletion of the APOBEC3B gene, samples with calculated copy numbers >1.41 and ≤3.44 
as no copy number change or balanced and samples with calculated copy numbers >3.44 as 
amplified for the APOBEC3B gene. Furthermore, 325 samples were measured in duplicate 
distributed over the 96-well sample plates and each 96-well plate included genomic DNA 
from breast cancer cell line OCUB-F as a control since this cell line has a two-copy deletion 
of APOBEC3B. 
 
Expression analysis 
APOBEC3B mRNA expression analysis has been performed previously for 1,491 breast 
cancer patients
15
. Extraction of RNA, synthesis of cDNA, reverse transcriptase quantitative 
PCR and quantification of transcripts was also described before
32
. Out of the 1,756 patients 
for whom we performed APOBEC3B copy number analysis in the current study, APOBEC3B 
mRNA expression data was available for 1,132 patients. 
 
Statistical analyses 
Because the number of patients carrying a two-copy deletion of APOBEC3B was small 
(N=16, 0.91%), we grouped patients with one-copy and two-copy deletions together. A χ2 or 
Fisher’s exact test (when the expected frequency was ≤5 in any of the groups) was used to 
evaluate the association between the APOBEC3B copy number status (i.e. deleted, balanced 
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or amplified) and the clinicopathological variables. To assess the association between the 
APOBEC3B copy number status and the ORR to either first-line tamoxifen treatment or 
first-line chemotherapy, we used a logistic regression model to calculate ORs and their 95% 
CIs. For visualization purposes, we performed survival analysis by the Kaplan-Meier method. 
The difference between survival curves for patients with either a deletion, no copy number 
change, or an amplification was calculated using the 3-sample logrank test. In addition, 
univariate Cox proportional hazards regression models including continuous calculated copy 
number values as covariate were performed to assess the association between APOBEC3B 
copy number and survival times (i.e. MFS in the adjuvant setting and PFS in the advanced 
setting). Finally, the correlation between APOBEC3B copy number and APOBEC3B 
expression was evaluated using Spearman’s rank correlation. All P-values were two-sided 
and P-values <0.05 were considered to be statistically significant. Analyses were performed 
using R, version 3.2.3, except for the power and sample size calculations shown in the 
Discussion. For these, we used the stpower cox tool in Stata version 13.1 (StataCorp, College 
Station, TX) assuming an alpha of 0.05, a beta of 0.2 (i.e. only in sample size calculations) 
and similar covariate standard deviations, allele frequencies, event probabilities and sample 
sizes (i.e. only in power calculations) as observed in the current study.  
 
Results 
We have performed APOBEC3B copy number analyses among 1,756 primary breast cancers 
and found no copy number change among 1,260 breast cancers. A two-copy deletion was 
identified in 16 (0.91%) breast cancers, whereas 171 (9.74%) breast cancers had a one-copy 
deletion. In addition, we detected an amplified APOBEC3B gene locus in 309 (17.26%) 
breast cancers. The minor allele frequency of the APOBEC3B deletion was 5.8% (203/3512) 
which is similar to the expected frequency in European population (i.e. 6.5%)
18
.  
Next, we evaluated the association between the APOBEC3B copy number status and the 
clinicopathological variables of the 1,756 breast cancer patients. We found that APOBEC3B 
copy number status was significantly associated with nodal status (P=0.041), but not with age, 
menopausal status, tumor size, tumor grade, tumor histology, ER, PR and HER2 status, and 
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adjuvant systemic therapy (Table 5.1). Despite the significant association between 
APOBEC3B copy number status and nodal status, however, no meaningful trend was 
observed (Table 5.1). 
To assess whether APOBEC3B copy numbers associate with clinical outcome in the 
adjuvant setting, we performed Kaplan-Meier survival analysis and Cox regression analysis 
in 1,604 LNN and LNP patients. No association between APOBEC3B copy number status 
and the length of MFS was found (P=0.14; Figure 5.2A). Moreover, calculated copy number 
values were also not associated with the length of MFS (HR=0.95, 95% CI=0.88-1.02, 
P=0.17; Table 5.2). Because all LNP patients were treated with adjuvant systemic therapy and 
we specifically wanted to evaluate the prognostic value of APOBEC3B copy number, we 
repeated these analyses in the cohort of 1,076 LNN patients that had not received any 
adjuvant systemic treatment. Again, we found no association between APOBEC3B copy 
number status and the length of MFS (P=0.84; Figure 5.2B), nor did we find an association 
between APOBEC3B calculated copy number values and the length of MFS (HR=1.00, 95% 
CI=0.90-1.11, P=0.96; Table 5.2). Also when we performed subgroup analysis in 769 ER- 
positive or 300 ER-negative untreated LNN patients (i.e. ER status was not available for 7 
patients), APOBEC3B copy numbers did not appear to have any prognostic value (Figure 
5.2C and 5.2D, Table 5.2). 
To evaluate the predictive value of APOBEC3B copy numbers, we had two cohorts of 
breast cancer patients available that were treated with first-line therapy for recurrent disease. 
First, we evaluated whether the calculated APOBEC3B copy number values could predict the 
response to first-line tamoxifen therapy in a cohort of 329 hormone-naive breast cancer 
patients with ER-positive primary breast cancer. No significant association was observed 
between APOBEC3B copy number and the ORR for tamoxifen therapy (OR=0.88, 95% CI= 
0.69-1.13, P=0.31; Table 5.3). Moreover, APOBEC3B copy number status was not associated 
with the length of PFS (P=0.25; Figure 5.2E), nor were calculated APOBEC3B copy number 
values associated with the length of PFS (HR=1.00, 95% CI=0.88-1.14, P=0.96; Table 5.4) in 
this cohort. Thus, APOBEC3B copy number is not a suitable biomarker to predict the type of 
response to tamoxifen therapy.  
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Table 5.2 Univariate Cox regression analysis to evaluate the association of calculated 
APOBEC3B copy number values with the length of MFS. 
 
Study cohort N Patients N Events 
Univariate analysis 
HR (95% CI)             P-value 
LNN+LNP     
     All patients 1,604 686 0.95 (0.88-1.02) 0.17 
LNN     
     All patients 1,076 366 1.00 (0.90-1.11) 0.96 
     ER+ patients 769 263 0.93 (0.82-1.06) 0.29 
     ER- patients 300 101 1.13 (0.94-1.35) 0.20 
 
N, number of; HR, hazard ratio; CI, confidence interval; LNN, lymph node negative; LNP, lymph node positive.  
Note: ER status was not available for 7 out of 1,076 patients.  
 
Table 5.3 Univariate logistic regression analysis of the overall response rate in patients 
treated with first-line tamoxifen and in patients treated with first-line chemotherapy for 
recurrent disease. 
 
Study cohort N Patients 
Univariate analysis 
OR (95% CI) P-value 
First-line tamoxifen    
     All patients 329 0.88 (0.69-1.13) 0.31 
First-line chemotherapy    
     All patients 224 0.96 (0.71-1.31) 0.80 
     CMF-treated patients 75 1.25 (0.70-2.21) 0.45 
     Anthracyclin-treated patients 149 0.79 (0.53-1.16) 0.22 
 
N, number of; OR, odds ratio; CI, confidence interval; CMF, cyclophosphamide/methotrexate/5- fluorouracil.  
Note: the type of response was ambiguous for 2 patients. 
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Figure 5.2 Kaplan-Meier survival analysis as a function of APOBEC3B copy number status.  
 
 
 
(A) In 1,604 patients of the lymph node negative (LNN) and lymph node positive (LNP) cohort combined. (B) 
In 1,076 LNN patients who did not receive any adjuvant systemic treatment. (C) In 769 ER-positive LNN 
patients who did not receive any adjuvant systemic treatment. (D) In 300 ER-negative LNN patients who did not 
receive any adjuvant systemic treatment. (E) In 329 ER-positive breast cancer patients who received first-line 
tamoxifen for recurrent disease. (F) In 226 breast cancer patients who received first-line chemotherapy for 
recurrent disease. (G) In 76 breast cancer patients who received first-line CMF-based chemotherapy for 
recurrent disease. (H) In 150 breast cancer patients who received first-line anthracycline based chemotherapy for 
recurrent disease. Differences between the survival curves were calculated with the 3-sample logrank test. 
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Table 5.4 Univariate Cox regression analysis to evaluate the association of calculated 
APOBEC3B copy number values with the length of PFS. 
 
Study cohort N Patients N Events 
Univariate analysis 
HR (95% CI) P-value 
First-line tamoxifen     
     All patients 329 304 1.00 (0.88-1.14) 0.96 
First-line chemotherapy     
     All patients 226 138 1.06 (0.88-1.29) 0.53 
     CMF-treated patients 76 52 0.91 (0.65-1.28) 0.58 
     Anthracyclin-treated patients 150 86 1.19 (0.93-1.52) 0.17 
 
N, number of; HR, hazard ratio; CI, confidence interval; CMF, cyclophosphamide/methotrexate/5- 
fluorouracil. 
Note: The length of PFS was censored at two months after the start of consolidation therapy. 
 
Next, we evaluated whether calculated APOBEC3B copy number values could predict 
the response to first-line chemotherapy in a cohort of 226 breast cancer patients. The 
calculated APOBEC3B copy number values were, however, not found to be associated with 
the ORR for chemotherapy (OR=0.96, 95% CI=0.71-1.31, P=0.80; Table 5.3). In addition, 
neither APOBEC3B copy number status, nor calculated APOBEC3B copy number values 
were associated with the length of PFS in these patients (P=0.42; Figure 5.2F and HR=1.06, 
95% CI=0.88-1.29, P=0.53; Table 5.4, respectively). The lack of a significant association 
with the ORR to chemotherapy and the length of PFS was also observed when performing 
subgroup analysis by type of chemotherapy (i.e. CMF versus anthracyclines; Table 5.3, 
Figure 5.2G and 5.2H, Table 5.4). APOBEC3B copy number is thus also not a predictive 
biomarker for the type of response to chemotherapy. 
In a previous study, we had analyzed APOBEC3B mRNA expression in 1,491 breast 
cancer patients and found that high APOBEC3B expression had prognostic value and was 
associated with poor outcome in untreated LNN patients with ER-positive breast cancer
15
. 
However, we did not find any association between APOBEC3B copy numbers and clinical 
outcome in the current study. As both APOBEC3B expression and APOBEC3B copy number 
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have been associated with a hypermutator phenotype
13,14,24
, we attempted to clarify this 
discrepancy by evaluating the correlation between APOBEC3B copy number and 
APOBEC3B mRNA expression. Out of the 1,756 patients for whom we performed 
APOBEC3B copy number analysis in the current study, we had APOBEC3B mRNA 
expression data available for 1,132 patients. Interestingly, although a correlation among 
APOBEC3B copy number and mRNA expression was observed, the correlation coefficient 
was low (spearman’s rho=0.26, P=2.2*10
-16
). This suggests that other mechanisms exist that 
affect APOBEC3B mRNA expression besides APOBEC3B copy number. 
 
Discussion  
APOBEC3B mRNA expression is upregulated in multiple tumor types and this has been 
shown to correlate with an increased mutational load, particularly an increase in C>T 
transversions
13,14
. In line with these findings, increased expression of APOBEC3B mRNA was 
associated with a poor prognosis in ER-positive breast cancer
15
. At the same time, the 29.5 kb 
deletion polymorphism of APOBEC3B was found to be associated with the increased breast 
cancer risk in different populations
19-21
, although these findings were not confirmed in a 
Swedish study
22
. Similar to APOBEC3B overexpression, the APOBEC3B deletion has been 
shown to correlate with an increased mutational load
24
. These findings may seem paradoxical, 
as loss of APOBEC3B should decrease the mutational load. However, the APOBEC3B 
deletion polymorphism not just deletes APOBEC3B. It also generates a novel fusion transcript 
(i.e. APOBEC3A under the control of the 3’UTR of APOBEC3B)
18
. Consequently, 
APOBEC3A mRNA was shown to become more stable, resulting in higher levels of 
APOBEC3A and, since APOBEC3A is a more efficient hypermutator than APOBEC3B, more 
severe DNA damage
23
. Thus, although the molecular mechanisms behind overexpression of 
APOBEC3B and the APOBEC3B deletion polymorphism are very different, they both result in 
a hypermutator phenotype. The hypothesis that the APOBEC3B deletion polymorphism thus 
may also be associated with clinical outcome is therefore plausible.  
In a study by Gohler et al., the APOBEC3B deletion polymorphism was however, not 
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associated with breast cancer specific survival in 782 breast cancer cases
22
. Moreover, Cescon 
et al. showed that the deletion was not associated with recurrence after treatment for early 
breast cancer in METABRIC
16
. Because both studies also included patients that were treated, 
no distinction could be made between pure prognosis and therapy response. In the current 
study, we examined separately the prognostic and predictive value of APOBEC3B copy 
number in a total of 1,756 breast cancer patients. No association between APOBEC3B copy 
numbers and the length of MFS was found among 1,076 LNN patients who had not received 
adjuvant systemic treatment (Figure 5.2B, Table 5.2). In addition, an association with the 
length of MFS was also not observed among ER-positive or ER-negative breast cancer 
patients. These results imply that APOBEC3B copy number is not a prognostic biomarker for 
breast cancer. The association between APOBEC3B copy number and the response to 
treatment in breast cancer patients that received either first-line tamoxifen or chemotherapy 
for recurrent disease was also evaluated. However, we found no association between the type 
of response for either tamoxifen or chemotherapy and APOBEC3B copy number. Thus, 
besides not having any prognostic value, APOBEC3B copy numbers also do not appear to 
have a predictive value for breast cancer patients.  
The copy number analyses for the adjuvant setting, except for the ER-negative LNN 
analysis, had sufficient power to conclude that there is no or only a marginal prognostic effect 
of APOBEC3B copy numbers in breast cancer patients (Figure 5.3). For the copy number 
analysis in the advanced setting involving patients treated with first-line tamoxifen, we could 
draw that same conclusion (Figure 5.3). However, for the copy number analysis involving 
patients treated with first-line chemotherapy, especially in the subgroup analyses by type of 
chemotherapy, we cannot exclude a modest effect of APOBEC3B copy numbers on the length 
of PFS (Figure 5.3). Therefore, replication of our results observed in the advanced 
chemotherapy setting in a larger sample size or population with a higher prevalence of the 
APOBEC3B deletion polymorphism could be needed. 
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Figure 5.3 Power as a function of the hazard ratio for APOBEC3B copy number in each of 
the analyzed subgroups.  
 
 
 
The dashed horizontal line crosses the curve of each subgroup at the minimal hazard ratio for which we had 80% 
power in our APOBEC3B copy number analyses. 
 
Another note is that the assay we used to determine APOBEC3B copy numbers does not 
discriminate between germline and tumor-specific (i.e. somatic) APOBEC3B deletion. This 
has no consequence for the accuracy of the germline copy number determination except for 
patients who carry a one-copy deletion and have strong amplification of the remaining 
APOBEC3B locus. Breast cancer patients who do not carry the germline deletion and have 
either a tumor-specific homozygous deletion or a heterozygous deletion of APOBEC3B in 
combination with a high tumor cell percentage may also be misclassified. In this respect, the 
observed amplification of the APOBEC3B allele is rather a somatic event than the result of an 
alteration in the germline. To date, there has been no report of the APOBEC3B locus being 
amplified in the germline. Interestingly, in a publically available SNP array data set of 344 
breast cancers (accession number EGAS00001001178
33
), APOBEC3A copy number status 
was equal to APOBEC3B copy number status in all tumors, suggesting that APOBEC3A is 
always amplified or deleted simultaneously with APOBEC3B during breast tumorigenesis.  
In our Kaplan-Meier survival analysis we grouped patients with one-copy deletion and 
two copy deletions together to provide a visualization of the estimated survival curves of 
patients with a deleted, balanced or amplified APOBEC3B gene. Unfortunately, the 
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population frequency of the 29.5 kb deletion polymorphism of APOBEC3B was too low in 
this Dutch cohort to analyze patients who carry a two-copy deletion separately. To illustrate 
this with a power calculation: we would need a sample size of 4,024 or 11,759 LNN patients 
to ensure a minimally detectable hazard ratio of 2 or 1.5, respectively, using a power of 80% 
and an alpha of 0.05. For this reason, evaluation of the clinical value of the two-copy deletion 
should preferably be done in breast cancer patients from the Asian or American population 
(i.e. population frequency of 36.9% and 57.7%, respectively)
18
. 
The observation that the APOBEC3B deletion polymorphism does not seem to have any 
impact on the clinical outcome for breast cancer patients, whereas increased expression of 
APOBEC3B mRNA does, strengthens the evidence that there are two different molecular 
mechanisms in place. Moreover, elevated levels of APOBEC3B mRNA have been shown to 
associate with cellular proliferation, whereas the APOBEC3B deletion polymorphism 
associated with activation of immune-related genes
16
. Interestingly, increased lymphocytic 
infiltration has been associated with a favorable outcome in some, but not all subtypes of 
breast cancer
34,35
. This is in contrast to what has been observed for increased APOBEC3B 
mRNA expression, which associated with increased proliferation and poor outcome
15
.  
Although we observed a correlation between APOBEC3B copy number and mRNA 
expression, this correlation was rather weak. As a consequence, the prognostic effect of 
increased levels of APOBEC3B mRNA is not necessarily caused by increased APOBEC3B 
copy numbers. Other mechanisms may exist that elevate APOBEC3B mRNA levels. Recently, 
it was shown that APOBEC3B interacts with ER to bind to ER binding sites, where it 
generates C to U transitions. Furthermore, the presence of APOBEC3B was necessary for 
histone modification, but also in order to recruit chromatin remodeling factors to ER binding 
sites
36
. This may very well explain why elevated levels of APOBEC3B mRNA are only 
prognostic in ER-positive breast cancer patients. Although the APOBEC3B deletion 
polymorphism does not have any prognostic or predictive value, it does appear to contribute 
to breast tumorigenesis by conferring an increased risk to develop breast cancer. However, 
still little is known regarding the role of APOBEC3A in breast cancer. Therefore, more studies 
should be done in order to investigate the precise effect of the APOBEC3B deletion 
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polymorphism and APOBEC3A-B hybrid transcript resulting from this deletion. This will 
provide more insight into APOBEC-mediated hypermutation.  
 
Supporting Information 
S5.1 Fig. Histogram of the ∆Ct values for all 1,756 measured DNA samples and cell line 
OCUB-F. 
S5.1 Table. Clinical data of all 1,756 breast cancer patients included in the study 
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Abstract 
In breast cancer, GATA3 mutations have been associated with a favorable prognosis and the 
response to neoadjuvant aromatase inhibitor treatment. Therefore, we investigated whether 
GATA3 mutations predict the outcome of tamoxifen treatment in the advanced setting. In a 
retrospective study consisting of 235 hormone-naive patients with ER-positive breast cancer 
who received tamoxifen as first-line treatment for recurrent disease, GATA3 mutations (in 
14.0% of patients) did not significantly associate with either the overall response rate (ORR) 
or with the length of progression-free survival (PFS) after start of tamoxifen therapy. 
Interestingly, among 148 patients for whom both mutation and mRNA expression data was 
available, GATA3 mutations associated with an increased expression of GATA3. However, 
only 23.7% of GATA3 high tumors had a mutation. Evaluation of the clinical significance of 
GATA3 mRNA revealed that it was associated with prolonged PFS, but not with the ORR, 
also in multivariate analysis. Thus, GATA3 mRNA expression, but not GATA3 mutation, is an 
independent predictor of prolonged PFS in ER-positive breast cancer patients who received 
first-line tamoxifen for recurrent disease. Besides GATA3 mutation other mechanisms must 
exist that underlie increased GATA3 levels. 
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Introduction 
Breast cancer is one of the most frequently diagnosed cancers in Western women. About 70% 
of all diagnosed breast cancers are estrogen receptor α (ER) positive. ER-positive breast 
cancers are well-differentiated and have a better outcome compared to other subtypes
1,2
. In 
this respect, tamoxifen is a frequently used and effective drug for patients diagnosed with 
ER-positive disease. However, half of ER-positive patients who receive tamoxifen as first-line 
therapy for recurrent disease do not respond to the treatment, due to intrinsic resistance, while 
the other half initially responding patients become resistant during treatment
3
. To better 
understand the mechanism involved in this intrinsic and acquired resistance and to be able to 
predict which patients are likely to respond to tamoxifen, the identification of novel markers 
predicting the efficacy of tamoxifen treatment is highly needed.  
GATA3 belongs to a family of zinc-finger transcription factors and is involved in 
embryogenesis and the differentiation of a variety of human tissues, including kidney, skin, 
breast and the central nervous system
4-8
. Both in the normal mammary gland and breast 
cancer tissue, GATA3 and ER expression are highly correlated
6,9
. In fact, GATA3 is 
expressed in the normal luminal epithelial cells where it maintains luminal cell 
differentiation
7
, whereas in breast cancer GATA3 is highly expressed in the luminal subtype, 
regulating differentiation and suppressing dissemination
7,10,11
. Furthermore, GATA3 is an 
integral component of the ER pathway as it regulates the pioneer factor FOXA1 and mediates 
ER binding by shaping enhancer accessibility
7,12
. Consequently, a large overlap exists 
between co-expressed genes for ER and GATA3, including many well-known ER pathway 
genes
13
. Since the expression of ER has important implications for both prognosis and 
treatment of breast cancers, several studies have assessed the association of GATA3 with 
clinical outcome. High GATA3 protein expression was shown to be associated with a lower 
grade, smaller tumor size and increased ER and PR expression
14-18
. In line with these findings, 
some, but not all, studies have shown that both GATA3 mRNA and GATA3 protein 
expression are independent prognostic markers, where high levels of GATA3 associate with a 
longer disease-free and overall survival in breast cancer patients
14,15,18-21
. Furthermore, in a 
small study of Parikh et al. high levels of GATA3 protein were predictive of hormone 
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responsiveness in ER-positive breast cancer patients
22
. In the neoadjuvant setting both 
GATA3 mRNA and GATA3 protein expression were shown to be predictive of a favorable 
response to chemotherapy
17,23
. 
The human GATA3 gene is a highly conserved gene located at 10p14-15 and consists of 
six exons which encode a protein of 444 residues
24
. Germline mutations of GATA3 cause a 
rare and complex disease of hypoparathyroidism, sensorineural deafness and renal 
insufficiency (HDR syndrome)
25
. In breast cancer, GATA3 is one of the most frequently 
mutated genes
26-29
 and sporadic heterozygous GATA3 mutations have been identified in 
approximately 5-20% of ER-positive breast cancers
30
. These mutations mostly cluster in the 
vicinity of the second zinc finger of GATA3
31
 and are virtually absent among ER-negative 
breast cancers. Interestingly, GATA3 mutations were correlated with improved disease-free 
and overall survival in breast cancer patients overall, but also in ER-positive breast cancer 
patients who received adjuvant endocrine therapy
32
. Furthermore, mutations in GATA3 were 
also shown to be correlated with response to neoadjuvant aromatase inhibition treatment
33
. 
This suggests that GATA3 mutation may be a determinant of the response to hormonal 
treatment.  
To investigate this hypothesis, we analyzed exons 5 and 6 of the GATA3 gene for 
mutations in 235 ER-positive primary breast cancers and evaluated the association of the 
identified mutations with the ORR and PFS of first-line tamoxifen therapy given for recurrent 
disease, as well as with GATA3 mRNA expression levels.  
 
Materials and methods 
Study population 
This retrospective study included 235 female breast cancer patients (Figure 6.1) and was 
approved by the Medical Ethical Committee of the Erasmus Medical Center Rotterdam, the 
Netherlands (MEC 02.953). In this study we adhered to the Code of Conduct of the 
Federation of Medical Scientific Societies in the Netherlands (http://www.fmwv.nl) and 
results are reported in accordance with the REMARK criteria on clinical reporting
34
. All 
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patients were diagnosed between 1979 and 1996 with measurable breast cancer disease, 
underwent primary surgery and were treated with tamoxifen as first-line treatment that was 
given for recurrent disease. Primary tumors were ER-positive and a minimum of 100mg of 
fresh frozen tissue was required for downstream DNA and RNA extraction
35
. ER and/or PR 
positivity was defined by ≥10fmol/mg cytosolic protein
36,37
 and ERBB2 overexpression was 
defined by a reverse transcriptase quantitative PCR (RT-qPCR) expression level ≥18
38
. The 
patients did not receive neo-adjuvant therapy or adjuvant hormonal treatment, did not 
experience previous other cancers and did not show subjective or objective toxicity
35
. There 
were 296 patients that fulfilled these criteria and from whom detailed clinical follow up and 
primary tumor DNA was available. However, 60 patients were excluded as the percentage of 
tumor cell nuclei was below 50%, precluding reliable mutation analysis. Furthermore, 
mutation analysis failed in 1 patient, totaling to n=235 included in the present study. From 
these, 84 patients underwent breast- conserving lumpectomy and 151 underwent modified 
mastectomy. In addition, 17 patients received adjuvant anthracycline-containing chemo- 
therapy and 14 received adjuvant chemotherapy without anthracyclines. There were 209 M0 
patients and 26 M1 patients. The median age at the time of the primary surgery was 57 years, 
while the median age at the start of first-line treatment was 61 years. Criteria for follow up 
and response to tamoxifen therapy were defined by standard International Union Against 
Cancer criteria of tumor response
39
. Complete and partial remission (together objective 
response) was observed in 4 and 34 patients, respectively, whereas 52 patients had 
progressive disease. From the patients with stable disease, 132 had no change for longer than 
6 months, whereas 13 patients had no change ≤6 months. According to the advice of the 
European Organization for Research and Treatment of Cancer
40
, we defined overall response 
as complete and partial remission including stable disease >6 months. As a result, 170 
patients were classified as responders to tamoxifen and 65 patients showed no response to 
tamoxifen. The median follow up of patients after start of tamoxifen therapy was 49 months 
(range: 4-208 months). At the end of the follow up, 224 patients had developed tumor 
progression and 196 patients had died.  
From 148 of the 235 patients we had total RNA of sufficient quality from the primary 
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tumor available (i.e. at an input of 10ng total RNA amplifiable for 3 reference genes within 
25 cycles) in order to perform GATA3 mRNA expression analysis by RT-qPCR. The 
clinicopathological variables of the patients are shown in Table 6.1.   
 
Figure 6.1 Study design and patient subsets analyzed for GATA3 mutation status and GATA3 
mRNA expression. 
 
 
 
The “All patients (N=296)” box represents all hormone naive patients diagnosed with recurrent breast cancer 
between 1979 and 1996 and were treated with first-line tamoxifen (details provided in the Materials and 
methods section). For the GATA3 mutation analysis 60 patients were excluded whose tumor cell nuclei 
percentage was below 50% and mutation analysis failed in one patient. From these 235 patients, total RNA of 
sufficient quality was available for 148 patients for GATA3 RT-qPCR analysis. Clinical endpoints were the 
overall response rate (ORR) and progression-free survival (PFS). 
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Mutation analysis 
Genomic DNA previously extracted from the fresh frozen primary breast tumor of 235 
patients
41
 and quantified by Picogreen was used at an input of 20ng to amplify GATA3 exon 5 
and 6 sequences. Subsequently, PCR amplicons were subjected to Sanger sequencing analysis 
on an ABI3130XL Genetic Analyzer (Applied Biosystems, Foster City, CA). All mutations 
were confirmed by Sanger sequencing using an independently amplified template. For the 
splice acceptor site mutations we performed an exonic reverse transcriptase PCR (RT-PCR) 
on a RNA template instead of PCR on a DNA template. We reported GATA3 mutations and 
predicted protein changes according the HGVS recommendations for the description of 
sequence variants
42
. PCR and sequencing primer sequences are available in Table S6.1A and 
B.  
 
Expression analysis 
Total RNA was extracted and cDNA was synthesized previously from the fresh frozen 
primary breast tumor of 148 patients as described before
35
. qPCR for GATA3 was performed 
in a Mx3000P
TM
 Real-Time PCR System (Agilent, Amsterdam, the Netherlands) using 
SensiFast Probe Lo-Rox master mix (GC biotech, Alphen aan den Rijn, the Netherlands) and 
a Taqman Gene expression Assay kit from Applied Biosystems (Hs00231122_m1; spanning 
exon 2 to 3; Nieuwerkerk aan den IJssel, the Netherlands) with 40 rounds of amplification as 
recommended by the manufacturer. In addition to a negative control (i.e. genomic DNA), we 
also included a standard curve of a serially diluted cDNA sample consisting of pooled breast 
cancer cDNA samples in each PCR plate. The latter was done to ensure that the PCR 
efficiency between plates was comparable and to normalize the data obtained from different 
plates and experiments. GATA3 mRNA expression levels for the samples were determined 
relative to the average Cq value of our reference gene set consisting of hydroxymethylbilane 
synthase (HMBS), hypoxanthine phosphoribosyltransferase 1 (HPRT1) and TATA-box 
binding protein (TBP) and quantified as follows: GATA3 expression = 2
Cq reference gene set – Cq 
GATA3 gene35
. PCR primer sequences for the reference genes are available in Table S6.1C. 
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Table 6.1 Association of GATA3 mutation status and GATA3 gene expression levels with 
clinicopathological variables in 235 ER-positive primary breast cancers. 
 
 
GATA3 mutation status  GATA3 expression level 
Variable 
Number 
of 
wild-type 
patients 
Number 
of 
mutant 
patients 
P-valu
e 
 
Number 
of 
patients 
Median 
GATA3 
expression
a
 
P-valu
e 
Total number 202 33   148 1.224  
Menopausal status
b
   0.22    0.25 
    premenopausal 44 11   33 0.891  
    postmenopausal 157 22   115 1.238  
Tumor grade   0.68    0.24 
    good/moderate 26 5   17 1.723  
    poor 116 15   86 1.010  
    unknown 60 13   45 1.242  
Tumor size   0.057    0.41 
    pT1 54 4   39 1.106  
    pT2 + unknown 120 27   93 1.276  
    pT3 + pT4  28 2   16 2.053  
Nodal status   0.36    0.37 
    N0   83 18   71 1.287  
    N1-3 43 7   30 1.172  
    N>3 63 7   37 0.767  
    unknown 13 1   10 0.778  
Dominant site of 
relapse 
  0.25    0.019 
    soft 24 1   13 0.276  
    bone 107 17   83 1.463  
    visceral 71 15   52 0.872  
Disease-free interval 
(m) 
  0.53    0.42 
    ≤12 53 8   39 1.225  
    13-36 78 16   64 1.144  
    >36 71 9   45 1.340  
PR protein status   0.28    0.0015 
    Positive 155 22   116 1.082  
    Negative 46 11   32 1.646  
    Unknown 1 0      
ERBB2 mRNA status   0.54    0.084 
    Positive 20 2   18 0.807  
    Negative 149 29   130 1.259  
    Unknown 33 2      
 
a
 Log2-transformed GATA3 gene expression levels. 
b
 At the start time of first-line tamoxifen treatment; m, months. 
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Statistical analyses 
A χ2 or a Fisher’s exact test (when the expected frequency ≤5 in any of the groups) was 
used to evaluate the relation between GATA3 mutation status and the clinicopathological 
variables. The relation between GATA3 mRNA expression levels and the clinicopathological 
variables was evaluated using either the two-sample Wilcoxon rank-sum test (for 2 categories) 
or the Kruskal-Wallis equality-of- populations rank test (for 3 categories). The association 
with tamoxifen response was analyzed with a logistic regression model to calculate odds 
ratios (ORs) and their 95% confidence intervals (95% CIs). PFS analysis was performed by 
the Kaplan-Meier method for visualization purposes and differences between survival curves 
were calculated by the Peto & Peto modification of the Gehan-Wilcoxon test (which puts 
more weight on the earlier events) for GATA3 mutation status and the log-rank test for GATA3 
gene expression. Univariate and multivariate Cox proportional hazards regression models 
were applied to calculate the hazards ratios (HRs) and 95% CIs in the analysis for the PFS. 
Log2-transformed expression values for GATA3 mRNA, ER and PR protein and ERBB2 
mRNA were used in logistic and Cox regression analysis. All P-values were two-sided and 
P-values smaller than 0.05 were considered to be statistically significant. Analyses were 
performed using R, version 3.2.3.  
 
Results 
Since at the start of this study all of the GATA3 mutations reported so far clustered in exons 5 
and 6 of the GATA3 gene, which encode the highly conserved second zinc finger required for 
DNA binding, we limited sequence analysis to these two exons. In total, we identified at least 
one GATA3 sequence variant in 54 out of the 235 primary tumors of patients with ER-positive 
recurrent breast cancer. A silent mutation in exon 5 (rs11567941; c.1257G>A; p.T122T; 
minor allele frequency (MAF)=0.02) was identified in 24 tumors, however, we did not 
consider this mutation to be pathogenic. Furthermore, we identified a frameshift insertion in 
22 tumors, a frameshift deletion in five tumors and a splice site deletion in six tumors (Table 
6.2). These mutations predicted prematurely truncated proteins in 14 tumors and proteins with 
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a longer C-terminal tail in 19 tumors. In total, we identified 33 GATA3 mutations that we 
considered to be pathogenic in 33 (14.0%) out of 235 ER-positive primary breast tumors.  
Next, we evaluated the association between GATA3 mutation status and the 
clinicopathological variables (Table 6.1), the ORR (Table S6.2) and the length of PFS after 
start of tamoxifen treatment (Table S6.2 and Figure 6.2A). We found no relation between 
GATA3 mutation and any of the clinicopathological variables (Table 6.1). Furthermore, 
GATA3 mutations did not significantly associate with the ORR for tamoxifen therapy in 
univariate logistic regression analysis (70.8% vs. 81.8%; OR=1.86, 95% CI=0.73-4.73, P= 
0.19; Table S6.2) or with the length of PFS in Kaplan-Meier (P=0.80; Figure 6.2A) and Cox 
regression analysis (HR=0.95, 95% CI=0.65-1.40, P=0.81; Table S6.2). Also subsetting by the 
type of mutation (i.e. mutations predicted to truncate versus elongate the protein) did not yield 
any significant differences. Although the number of patients were small, survival curves 
appeared very similar. However, logistic regression analysis did show that the traditional 
predictive factor disease-free interval was associated with the efficacy of tamoxifen therapy 
(Table S6.2). Similarly, the traditional predictive factors dominant site of relapse, disease-free 
interval and the level of PR protein expression were found to be associated with PFS (Table 
S6.2). These results implied that GATA3 mutation status is not a significant predictor for the 
outcome of tamoxifen therapy in patients with recurrent disease. 
Out of the 235 tumors for which we performed GATA3 mutation analysis, we were able to 
perform GATA3 mRNA expression analysis by RT-qPCR for 148 tumors. In 25 out of these 
148 tumors we identified a GATA3 mutation and 123 tumors were wild-type. Interestingly, 
GATA3 expression levels were higher among mutant GATA3 tumors (i.e. irrespective of the 
predicted effect of the mutation) than wild-type GATA3 tumors (P=0.0019). Eighteen tumors 
(72.0%) with GATA3 mutations had high GATA3 expression levels (i.e. above the median) 
while only seven tumors (28.0%) with GATA3 mutations had low GATA3 expression levels 
(i.e. below the median). However, out of the 76 GATA3 high expressing tumors, only 18 
(23.7%) had a mutation in the GATA3 gene. Because the high levels of GATA3 mRNA were 
only partially explained by a mutation in GATA3 itself, we hypothesized that GATA3 
expression instead of mutation might be associated with the outcome of tamoxifen treatment.  
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Table 6.2 Identified GATA3 mutations among 235 ER-positive primary breast cancers. 
 
Location Nucleotide change Predicted protein change 
Number of 
patients  
Exon 5 c.925-3_925-2delCA p.S309Pfs*45 6 
Exon 5 c.961_962delTG p.C321Sfs*31 1 
Exon 5 c.983_984insC p.W329Lfs*25 1 
Exon 5 c.1002_1003insG p.G335Gfs*18 1 
Exon 5 c.1003delG p.G335Gfs*20 1 
Exon 5 c.1007_1008insC p.V341Vfs*15 1 
Exon 5 c.1021_1022insC p.A341Afs*11 1 
Exon 5 c.1033_1034insAC p.Y345Yfs*11 1 
Exon 5 c.1035_1036insT p.Y346Lfs*7  1 
Exon 6 c.1195_1196delAG p.R399Tfs*108 1 
Exon 6 c.1202_1203insG p.S402Vfs*106 1 
Exon 6 c.1202_1203insGTCC p.S403Vfs*106 1 
Exon 6  c.1206_1207insT p.S403Ffs*105 2 
Exon 6 c.1207_1208 insC p.L404Pfs*103 1 
Exon 6 c.1222_1223insC p.P409Afs*99 2 
Exon 6 c.1223_1224insT p.P409Sfs*100 1 
Exon 6 c.1223_1224insG p.P409Afs*99 1 
Exon 6 c.1257_1258insC p.T421Hfs*87 1 
Exon 6 c.1263_1282del20 p.M423Vfs*78 1 
Exon 6  c.1271_1272insC p.P425Afs*82 2 
Exon 6 c.1277_1278insA p.S427Ifs*81 2 
Exon 6  c.1304_1305insC p.S437Lfs*71 2 
Exon 6 c.1305delC p. S437Pfs*39 1 
 
Nomenclature for the identified nucleotide changes and predicted protein changes is according the HGVS 
recommendations for the description of sequence variants
42
. * Stop codon. 
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Figure 6.2 Kaplan-Meier analysis of progression-free survival.  
 
 
 
(A) according to GATA3 mutation status for 235 ER-positive breast cancer patients who received first-line 
tamoxifen therapy for recurrent disease. The difference between the survival curves was calculated using the 
Peto & Peto modification of the Gehan–Wilcoxon test. (B) Dichotomized at median GATA3 expression level for 
148 ER-positive breast cancer patients who received first-line tamoxifen therapy for recurrent disease. The 
difference between the survival curves was calculated using the log-rank test. 
 
To evaluate this, we made use of the GATA3 mRNA expression data for all 148 primary 
breast tumors from recurrent breast cancer patients that we had generated by RT-qPCR. We 
found that GATA3 expression was associated with dominant site of relapse and PR protein 
status, but not with menopausal status, tumor grade, tumor size, nodal status, disease-free 
interval or ERBB2 mRNA status (Table 6.1). In univariate logistic regression analysis, we 
found no association of GATA3 expression level with the ORR for tamoxifen (64.9% versus 
66.2%; OR=1.12, 95% CI=0.90-1.41, P=0.31; Table 6.3). Additionally, menopausal status, 
dominant site of relapse and ER protein, PR protein and ERBB2 mRNA expression levels 
were also not associated with the ORR for tamoxifen, in contrast to disease-free interval 
(Table 6.3). GATA3 expression was, however, associated with the length of PFS, as it was 
prolonged for patients with tumors with high GATA3 mRNA levels compared to those with 
low levels (P=0.033; Figure 6.2B). Concordantly, in univariate Cox regression analysis, high 
GATA3 expression levels were significantly associated with a prolonged PFS (HR=0.87, 95% 
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CI=0.78-0.98, P=0.017; Table 6.4). Besides GATA3 expression levels, also disease-free 
interval, but not menopausal status, dominant site of relapse and ER protein, PR protein and 
ERBB2 mRNA expression levels, were associated with the length of PFS (Table 6.4). In 
multivariate analysis, by including GATA3 expression in a model with all the traditional 
predictive factors, GATA3 expression levels were significantly associated with a prolonged 
PFS (HR=0.85, 95% CI=0.75-0.96), P=0.0079; Table 6.4). These results imply that GATA3 
mRNA expression, rather than genetic aberration of the gene alone, is an independent 
predictor for the length of PFS in hormone-naive ER-positive breast cancer patients treated 
with first-line tamoxifen for recurrent disease.  
 
Table 6.3 Univariate logistic regression analysis of the overall response rate in 148 ER 
positive breast cancer patients treated with first-line tamoxifen for recurrent disease. 
 
Variable 
Univariate analysis 
OR (95% CI)             P-value 
Base model:   
Menopausal status
a
   
     premenopausal 1  
     postmenopausal 1.83 (0.83-4.03) 0.13 
Dominant site of relapse   
     soft 1  
     bone 0.43 (0.11-1.69) 0.23 
     visceral 0.81 (0.20-3.40) 0.78 
Disease-free interval (m)   
     ≤12 1  
     13-36 4.70 (1.98-11.11) 0.00043 
     >36 3.54 (1.43-8.76) 0.0063 
ER protein expression 1.12 (0.95-1.33) 0.17 
PR protein expression 1.06 (0.95-1.18) 0.30 
ERBB2 mRNA expression 1.07 (0.95-1.22) 0.26 
Additions to the base model:   
GATA3 mRNA expression 1.12 (0.90-1.41) 0.31 
 
a
 At the start time of first-line tamoxifen treatment; m, months. 
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Table 6.4 Univariate and multivariate Cox regression analyses of progression-free survival in 
148 ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease. 
 
 
Variable 
Univariate analysis  Multivariate analysis 
HR (95% CI)            P-value  HR (95% CI)            P-value 
Base model:      
Menopausal status
a
      
    premenopausal 1   1  
    postmenopausal 0.73 (0.49-1.09) 0.12  0.84 (0.54-1.29) 0.42 
Dominant site of relapse      
    soft 1   1  
    bone 1.88 (0.99-3.57) 0.054  2.36 (1.21-4.63) 0.012 
    visceral 1.47 (0.76-2.86) 0.26  1.74 (0.86-3.53) 0.13 
Disease-free interval (m)      
    ≤12 1   1  
    13-36 0.66 (0.43-0.99) 0.046  0.61 (0.40-0.93) 0.021 
    >36 0.56 (0.36-0.88) 0.012  0.59 (0.37-0.94) 0.026 
ER protein expression  0.95 (0.87-1.03) 0.22  0.97 (0.88-1.06) 0.49 
PR protein expression  0.95 (0.90-1.00) 0.051  0.95 (0.89-1.01) 0.077 
ERBB2 mRNA expression 0.98 (0.91-1.05) 0.62  0.98 (0.91-1.06) 0.62 
Additions to the base model:       
GATA3 mRNA expression 0.87 (0.78-0.98) 0.017  0.85 (0.75-0.96) 0.0079 
 
a
 At the start time of first-line tamoxifen treatment; m, months. 
 
Discussion 
GATA3 is one of the most frequently mutated genes in breast cancer
26-29
 and mutations in 
GATA3 are associated with improved survival
32
. Because GATA3 mutations are also 
associated with both a favorable outcome among ER-positive patients who received adjuvant 
endocrine treatment as well as response to neoadjuvant aromatase inhibitors
32,33
, we here 
evaluated whether GATA3 mutations measured in the primary tumor (i.e. all ER positive) can 
determine the outcome of patients treated with first-line tamoxifen for recurrent disease. 
However, GATA3 mutations were not significantly associated with either the ORR or with 
PFS in 235 ER-positive breast cancer patients who received tamoxifen as a first-line therapy 
for recurrent disease (Table S6.2 and Figure 6.2A). Even though GATA3 mutations were 
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associated with increased levels of GATA3 expression, only GATA3 expression was found to 
be an independent predictor for prolonged PFS (Table 6.4). Our results suggest that not 
GATA3 mutation, but rather GATA3 expression predicts the length of PFS. This result will 
need to be validated in an independent patient population. 
Jiang et al. have previously shown that GATA3 mutations were associated with improved 
survival in both the TCGA cohort as well as the Chinese FUSCC cohort
32
. In the TCGA 
cohort, however, this prognostic effect was limited to ER-positive breast cancer cases (overall 
survival P=0.041) in contrast to all cases in the FUSCC cohort (overall survival P=0.033). 
Furthermore, in the FUSCC cohort, GATA3 mutations were also associated with longer 
disease-free survival in ER-positive patients who received adjuvant endocrine treatment 
(P=0.046), which may suggest a role for GATA3 mutation in the efficacy of endocrine therapy. 
However, our results do not show that GATA3 mutations are associated with the outcome of 
tamoxifen treatment in 235 ER-positive patients who were treated with first-line tamoxifen 
for recurrent disease (Table S6.2 and Figure 6.2A). This suggests that the improved 
disease-free survival of patients with GATA3 mutated tumors in the FUSCC cohort can be 
attributed to a pure prognostic association of GATA3 mutation rather than its role as a 
predictive factor for tamoxifen efficacy. Noteworthy, however, is that GATA3 mutations in the 
neoadjuvant setting were a predictive marker of favorable outcome of aromatase inhibitor 
treatment
33
. In that study, 77 ER-positive breast cancer samples were sequenced and GATA3 
mutations were more frequently present in aromatase inhibitor sensitive tumors (P=0.01). The 
apparent discrepancy between our study and the study of Ellis et al. might be attributable to a 
difference in the mechanism of action between aromatase inhibitors and tamoxifen or, 
probably more likely, due to the difference in primary versus recurrent disease receiving 
endocrine treatment and the used endpoints.   
At the gene expression level, high GATA3 has consistently and independent of other 
clinicopathological predictors been linked to a better outcome
14,19
, but at the protein level the 
prognostic effect of GATA3 remains controversial
15,18,20,21
. Higher sensitivity and/or accuracy 
of gene expression compared with protein expression measurement methods could very well 
explain poor consistency at the protein level. Interestingly, in a small study including only 28 
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patients and examining the expression of GATA3 by immunohistochemistry, Parikh et al. 
found that GATA3 expression predicted hormone responsiveness in breast cancer as six of 14 
(43%) cancers were GATA3 negative in the hormone-unresponsive group and 0 of 14 (0%) 
cancers were GATA3 negative in the hormone-responsive group (P=0.031)
22
. These results 
are in line with the current study, where we analyzed GATA3 gene expression levels in 148 
ER-positive recurrent breast cancer patients who were treated with first-line tamoxifen and 
found that high levels of GATA3 were associated with a prolonged PFS (Figure 6.2B). 
Moreover, in multivariate analysis, GATA3 expression was an independent predictor of 
progression-free survival (Table 6.4). The predictive effect of GATA3 at the protein level, 
however, requires independent examination. 
In the current study, we also observed that breast cancers with a GATA3 mutation had 
significantly higher GATA3 expression levels, although only GATA3 expression appeared to 
be associated with prolonged PFS. Importantly, from the 76 breast cancers with high GATA3 
expression levels, 18 (23.7%) had a GATA3 mutation. Thus, a significant fraction (n=58, 
76.3%) of the GATA3 high breast cancers does not have a GATA3 mutation. In order to be 
certain that we did not miss any mutations located outside exon 5 and 6, we additionally 
sequenced the other coding exons (i.e. exon 2-4) of the GATA3 gene in these 58 breast 
cancers, but did not find any additional mutations. This not only confirms that the vast 
majority of GATA3 mutations are actually located in exon 5 and 6, but this also suggests that 
there are other mechanisms besides GATA3 mutation that may be responsible for the high 
GATA3 expression in ER-positive breast cancers with a wild-type GATA3 gene. As the 
GATA3 transcription factor reshapes gene loci by recruiting chromatin remodeling 
complexes, mutations of these proteins present in these complexes or other upstream pathway 
members could very well be involved in these mechanisms. For example, GATA3 expression 
was recently also reported to be increased by Wnt/β-catenin pathway activation in 
adipocytes
43
. Identification of these players may lead to a better understanding of the 
mechanisms of resistance to tamoxifen treatment by transcriptional regulation through 
GATA3, the crucial transcription factor regulating luminal differentiation in the mammary 
gland. 
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In conclusion, not GATA3 mutation, but GATA3 gene expression is associated with 
prolonged PFS in ER-positive breast cancer patients who received first-line tamoxifen 
treatment for recurrent disease. In addition, GATA3 mutation leads to an increased GATA3 
mRNA expression, but besides genetic aberration of GATA3, other mechanisms are in place 
to explain the increased GATA3 levels in GATA3 wild-type tumors with high GATA3 mRNA. 
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Discussion  
Breast cancer is the most common cancer in women worldwide while incidence rates vary 
widely. The survival rates are heading toward a positive trend
1
. Intensive research efforts 
have been performed to develop novel technologies and therapeutics for a clinical application 
in patients suffering from breast cancer. The purpose of this thesis is to contribute to the 
development of breast cancer survival. In this thesis, we aimed to identify novel genetic 
variants associated with breast cancer risk to facilitate early detection of breast cancer. 
Furthermore, we aimed to discover new prognostic and predictive biomarkers for breast 
cancer to improve personalized treatment.  
 
7.1 Discovering genetic variants for breast cancer susceptibility 
Breast cancer is a genetic disease and arises as a consequence of genetic mutations including 
somatic and germline mutations. The development of breast cancer is related with many 
factors and a family history of breast cancer is a major one. Familial breast cancer has been 
associated with germline mutations in susceptibility genes. Three well-defined classes of 
breast cancer susceptibility genes have been identified: high-, moderate-, and low-risk 
genes/alleles. High-risk susceptibility genes include BRCA1
2
, BRCA2
3
, CDH1
4
, PALB2
5
, 
PTEN
6
, STK11
7
 and TP53
8
. Mutations in high-risk genes are very rare in frequency in the 
population and account for around 30% of the familial risk of breast cancer
9
. Moderate-risk 
genes include ATM, CHEK2, NBS1 and RAD50
10
. The moderate-risk genes confer 5% 
increased familial breast cancer risk and mutations in those genes are rare in frequency
11
. 
More than 90 low-risk genes/alleles have been identified through genome wide association 
studies (GWAS). The low-risk genes/alleles are quite common in frequency and confer 16% 
of the familial breast cancer risk
12
. Altogether, these three classes of susceptibility 
genes/alleles explain about 51% of familial breast cancer risk and the remaining 49% of 
familial breast cancer risk still remains to be explained since twin studies have suggested that 
a large part of the remaining familial breast cancer risk is due to genetic factors
13
.  
 Early detection of breast cancer is important for a favorable survival of breast cancer 
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patients. For early detection of breast cancer, we need to estimate the significant risk for 
developing breast cancer of individuals at an early stage. Breast cancer susceptibility 
genes/alleles can be applied clinically in risk estimation and risk prediction models 
combining breast cancer susceptibility genes/alleles are useful to make decisions on screening 
and prevention
14,15
. The combined effects of the low-risk SNPs are able to increase breast 
cancer risk significantly and thus polygenic risk scores can be used to stratify breast cancer 
risk
16
. In addition, the inclusion of non-genetic risk factors, such as mammographic density, 
weight gain and vitamin D deficiency into existing models may also improve breast cancer 
risk prediction
17
. For example, the Gail model has been commonly used to estimate breast 
cancer risk in women
18
 and it is valuable to add genetic information from low-risk SNPs to 
the Gail model
19-21
. Moreover, the BOADICEA model which is a genetic model for familial 
breast cancer susceptibility predict the risk of developing breast cancer by combining the 
effects of BRCA1, BRCA2 and all the known low-risk genes
14,22
. However, these risk 
prediction models are not good enough yet, as the current susceptibility genes/alleles only 
explain about 51% of familial breast cancer risk. Therefore, it is necessary to identify more 
susceptibility genes/alleles based on further genome-based research
23
. The improvement of 
clinical risk prediction is necessary to detect individuals with breast cancer risk earlier so that 
they might benefit from preventive measures.  
 
7.1.1 Methods to identify novel breast cancer susceptibility genes  
In the past, three main methods have been used to identify genetic breast cancer susceptibility 
genes: linkage analysis, mutational screening of candidate genes, and association studies
24
. 
Linkage analysis is suitable for mapping high-risk susceptibility genes only. BRCA1 and 
BRCA2 were identified by linkage analysis in breast cancer families and positional cloning. 
Other high-risk susceptibility genes such as CDH1, PTEN and STK11 were also identified by 
positional cloning. Mutations in these genes were found to be associated with hereditary 
diffuse gastric cancer syndrome (CDH1), Cowden syndrome (PTEN) and Peutz-Jeghers 
syndrome (STK11), syndromes which all are also associated with an increased risk of breast 
cancer. Since additional high-risk genes, if these exist at all, are probably very rare, linkage 
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analysis is not a suitable method to identify them. If a susceptibility gene/mutation is 
infrequently present within the breast cancer families under investigation, linkage analysis 
becomes less powerful. Genome-wide linkage analyses for lower frequency genes is only 
valuable in a more homogenous collection of families. Alternatively, large scale sequencing 
projects will probably be the most optimal method to identify further high-risk genes.  
BRCA1 and BRCA2 play important roles in the maintenance of genomic stability and 
are involved in the DNA repair pathway. Mutations in genes whose protein products operate 
in DNA repair pathways, like BRCA1 and BRCA2, may also be associated with breast cancer 
risk. Actually, the known intermediate-risk genes are all involved in DNA repair pathways
10
. 
All of the intermediate-risk genes were identified by candidate-gene or population-based 
approaches. NBS1 together with MRE11 and RAD50 plays an important role in the early 
response to double-strand breaks. NBS1 and RAD50 are current intermediate-risk genes
10
 and 
it seems that MRE11 is also involved in breast cancer susceptibility
25,26
. Additional genes 
involved in DNA repair and related pathways are thus candidate breast cancer susceptibility 
genes. Over the past years mutational screening of candidate genes has been a successful 
approach to identify novel intermediate-risk genes. However, in the current era, whole 
genome sequencing in familial case-control studies will be more efficient to reveal further 
intermediate-risk genes. 
Genome wide association studies (GWAS) have been performed to identify low-risk 
alleles. Until today, more than 90 common low-risk alleles have been identified. It is 
estimated that another 1,000 low-risk loci may still remain unidentified and could confer 
another 14% of familial breast cancer risk
27
. Further low-risk alleles may be identified 
through even larger GWAS combined with imputation or genome- wide sequencing projects. 
As the majority of identified low-risk susceptibility alleles are not located in or near genes, 
post-GWAS analysis is needed to identify the causal variants and determine their function
28
. 
Importantly, further identification of breast cancer susceptibility genes/alleles is needed to 
improve upon the current breast cancer risk prediction models to facilitate early detection of 
breast cancer. 
 In Chapter 3 and 4, we aimed to discover new genes or alleles associated with breast 
132 | P a g e  
 
cancer risk by using a candidate-gene approach. Based on previous studies, we focused on 
HOXB13 gene mutations and the functional variant rs2735383 in NBS1. 
 
7.1.2 Mutations in the HOXB13 gene and breast cancer susceptibility  
In Chapter 3, we investigated the association of HOXB13 mutations with breast cancer risk. 
HOXB13 p.G84E had been reported to be associated with prostate cancer and conferred a 4- 
to 5-fold increased prostate cancer risk
29
. HOXB13 plays an important role in prostate cancer 
development
30
. The rare HOXB13 p.G84E variant was observed to be associated with 
prostate cancer risk by linkage analysis and candidate gene sequencing of 200 genes at the 
17q21-22 linkage region
29
. Then several groups validated the association of HOXB13 p.G84E 
with prostate cancer risk
31-33
. In breast cancer tissue, high expression of HOXB13 has been 
shown to mediate poor response to tamoxifen therapy
34
. Moreover, a high ratio of HOXB13: 
IL17BR expression was found to be a prognostic and predictive biomarker for ER-positive 
breast cancer patients
35,36
. Based on these observations, we hypothesized that the HOXB13 
p.G84E mutation might also be associated with breast cancer risk. At the start of the project, 
three studies had analyzed this association and obtained contradictory results
37-39
. In the study 
by Alanee et al. the HOXB13 p.G84E mutation was shown to confer an increased breast 
cancer risk
37
, however, this association was not found in the other two studies
38,39
. In our 
study, HOXB13 p.G84E was found not to be associated with breast cancer risk. We also 
detected another recurrent mutation, p.R217C, which had not been associated with prostate 
cancer risk
40,41
. Although we found that this mutation was 3.5 fold more prevalent in cases 
than controls, the association between HOXB13 p.R217C and breast cancer risk was not 
statistically significant. The limitation of our study was that the sample size was small. Due to 
the low population frequency, producing wide confidence intervals, the association may have 
failed to be detected. Therefore, it is worthwhile to evaluate the association of HOXB13 
p.R217C with breast cancer risk in a larger study of 6,237 cases and 6,237 controls. Therefore, 
the HOXB13 p.R217C mutation, G84E mutation, as well as two other less frequent mutations 
that were identified from our study (i.e. p.190L, p.R268Q) have been genotyped within the 
Breast Cancer Association Consortium (BCAC) on the OncoArray. 
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Figure 7.1 The mechanism of HOXB13 as a prostate cancer susceptibility gene. 
 
 
 
HOXB13 is recruited to a prostate cancer-associated SNP rs339331 and enhances RFX6 expression to promote 
prostate cancer metastasis
44
. 
 
In prostate cancer, HOXB13 regulates the transcription of androgen receptor (AR) target 
genes
42
. HOXB13 was shown to bind to a prostate cancer-associated SNP located in a 
FOXA1 and AR binding site that enhanced RFX6 expression to promote prostate cancer 
metastasis (Figure 7.1)
43,44
. In breast cancer, ER and HOXB13 have been shown to regulate 
each other’s expression
34,45
. Breast cancer risk-associated SNPs are enriched in the cistromes 
of FOXA1 and ER
46
. If the association of HOXB13 mutations is found in a larger study, it 
should be established for instance by ChIP-seq if the HOXB13 cistrome overlaps with 
ER-FOXA1 cistromes providing support for the involvement of HOXB13 in ER-FOXA1 
transcriptional regulation. Furthermore, by the determining the overlap between risk- 
associated SNPs and HOXB13 binding sites as identified by ChIP-seq, risk-associated SNPs 
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directly affect HOXB13 binding can be identified. Moreover, the genomic regions to which 
HOXB13 when bound to these SNPs interact and thus potentially regulate their gene 
expression can be revealed by 3C (chromosome conformation capture) which is a technique 
to study the spatial organization of chromatin in 3D. Finally, to investigate whether HOXB13 
p.R217C affects the HOXB13 binding function, ChIP-seq profiles can be generated for 
p.R217C mutant transfectants and compared with the ChIP-seq profile for wild-type 
HOXB13. 
 
7.1.3 The NBS1 rs2735383 variant and breast cancer susceptibility 
In Chapter 4, we investigated the association of NBS1 rs2735383 with breast cancer risk. 
The DNA damage response plays an important role in susceptibility to breast cancer. NBS1 is 
one of the mediators involved in the DNA damage response. NBS1 is a moderate-risk breast 
cancer gene, and the 657del5 mutation confers a three-fold increased breast cancer risk
47
. The 
functional variant rs2735383 in the 3’UTR of NBS1, which could regulate the expression of 
NBS1, has been reported to be associated with the risk of lung cancer
48
 and colorectal 
cancer
49
. However, the association of NBS1 rs2735383 with breast cancer risk was still 
unclear. Based on these findings in lung and colorectal cancer, we hypothesized that NBS1 
rs2735383 might be associated with breast cancer risk. In our study, NBS1 rs2735383 was 
firstly genotyped in 1,159 controls and 1,269 cases from RBCS study but we did not observe 
an association of NBS1 rs2735383 with increased breast cancer risk. As the RBCS cohort is 
relatively small and thus our analysis likely underpowered to find a small effect size, we 
analyzed NBS1 rs2735383 through imputation in 47,640 breast cancer cases and 46,656 
controls from BCAC studies. But also in this sufficiently sized cohort to do a properly 
powered analysis, we did, however, not find any evidence for an association of rs2735383 
and increased breast cancer risk in the overall analysis and also not in appropriate subgroup 
analysis.  
In a small study by Wu et al., rs2735383 was shown not to be associated with overall 
breast cancer risk, while an association was identified with reproductive factors including age, 
age at menarche and menopause, menopausal status, number of pregnancies and abortions, 
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breast-feeding status and family history of breast cancer in first-degree relatives
50
. We did not 
find an association in these same subgroups. The sample size in the study by Wu et al. was 
not large and thus statistical power was only around 60%. All studies presenting novel risk 
alleles need to be validated in larger studies and different populations to provide accurate risk 
estimates. We did not replicate the findings by Wu et al. and we concluded NBS1 rs2735383 
is not associated with increased breast cancer risk.  
In lung cancer, rs2735383 influences the binding ability of microRNA-629 and affects 
NBS1 transcriptional activity and as result expression level. Low expression of NBS1 may 
decrease DNA repair efficiency and thus increase lung cancer risk
48
. In colorectal cancer, 
microRNA-509-5p only binds to the 3’UTR of NBS1 containing the rs2735383 C allele and 
as a results decreases the expression level of NBS1
49
. MicroRNA-499 and microRNA-508 
were also shown to bind to the 3’UTR of NBS1
50
. In breast cancer cells, only microRNA-629 
is expressed at substantial levels, however we do not know the expression of these 
microRNAs in normal mammary epithelial tissue. In our study, rs2735383 was not associated 
with breast cancer risk which might indicate that these microRNAs are not expressed in 
normal breast tissue and thus cannot downregulate NBS1 or other factor compromise their 
effects. In further work, the microRNA expression levels in normal mammary tissue and their 
correlation with rs2735383 should be evaluated to understand the lack of an association of 
this SNP with breast cancer risk. 
 
7.2 Discovering genetic markers for clinical outcome of breast cancer 
Breast cancer is a heterogeneous disease and its classification has evolved over the years. 
Intrinsic subtypes are essential in decision on the type of therapies as these subtypes show 
different biological and clinical behavior
51
. In order to provide patients with individualized 
treatments, prognostic and predictive biomarkers are needed (Figure 7.2). Tumor grade
52
 and 
tumor stage
53
 are traditional clinical factors while ER, PR, HER2 and Ki67 are traditional 
molecular prognostic and/or predictive biomarkers
54
. The use of these classical biomarkers 
for the prediction of treatment response and clinical outcome of breast cancer patients and 
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part of the current guideline for the treatment of breast cancer has been well established. 
Recently various prognostic and predictive gene expression signatures have been identified. 
For example, a high HOXB13:IL17BR ratio has been found to be associated with a high risk 
of recurrence and predicted poor response to tamoxifen
35,36
. The multiprotein signature 
uPA/PAI-1 and several multigene signatures such as MammaPrint and OncotypeDX have also 
been identified as prognostic and predictive biomarkers
55
. However, only a few of them have 
been brought to clinical utility so far. To further improve individualized treatment for breast 
cancer patients as well as to understand the disease, we need to identify novel prognostic and 
predictive biomarkers. Further molecular markers for breast cancer might be involved in 
tumor driver and suppressor pathways, the DNA damage response pathway and pathways 
promoting metastasis
56
. For example, several molecular factors such as p53, p14
ARF
, cyclin 
D1, cyclin E, BRCA1, BRCA2 and VEGF amongst others have been identified. In addition, 
epithelial-mesenchymal transition (EMT) is one of the mechanisms of cancer metastasis and 
several transcription factors have been shown to promote EMT. Recently, the prognostic 
value of transcription factors promoting EMT such as FOXC1, SIX1 and TWIST1 in breast 
cancer patients has been studied and were associated with adverse outcome in breast 
cancer
57,58
. The prognostic and predictive value of the immune signatures and numbers of 
tumor-infiltrating lymphocytes (TILs) in relationship with breast cancer outcome has also 
been revealed
59
. High expression of CXCR4 in triple negative breast cancer might indicate a 
poorer survival
60 
while high CXCR4 mRNA expression was associated with a good survival
61
. 
Two chemokines CCL2
62
 and CCL5
63
 have been shown to be unfavorable prognostic markers 
for breast cancer patients. Total TILs have been shown to be associated with a better 
prognosis
64,65
 and CD8
+ 
T cells, which are the majority of TILs, are also favorable prognostic 
factors for breast cancer patients
66,67
. In addition to the molecular tumor derived biomarkers, 
blood-derived biomarkers including circulating tumor cells (CTCs) and cell-free DNA 
(cfDNA) have been demonstrated to have the prognostic value in breast cancer. Elevated 
numbers of CTCs are associated with unfavorable clinical outcomes
68
. CfDNA are short 
fragments of nucleic acids in the circulation and, like CTCs, can be detected in blood. In 
breast cancer, higher total serum cfDNA was associated with worse survival
69,70
. In additional, 
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ER mutations in cfDNA are associated with poor outcome in metastatic breast cancer
71
. 
However, the prognostic and predictive value of these novel biomarkers need to be validated 
in clinical trials before clinical utility is warranted.  
In Chapter 5 and 6, we aimed to discover new genetic markers that predict the prognosis 
of breast cancer patients and response to therapy. We focused on two genes: APOBEC3B and 
GATA3. 
 
Figure 7.2 Prognostic and predictive biomarkers in breast cancer. 
 
 
 
 
7.2.1 Discovering the prognostic and predictive value of the APOBEC3B deletion 
polymorphism 
Somatic mutations do not arise at random as they occur in a genetic context suggesting 
specific processes are involved. These characteristic patterns of somatic mutations were 
designated mutational signatures and 12 distinct mutational signatures in total have been 
defined in breast cancer
72,73
. Signature 2 and 13 are characterized by C>T and C>G 
substitutions that are attributed to the AID/APOBEC family of cytidine deaminases. 
APOBEC3B is a member of APOBEC3 gene family and able to convert cytosine to uracil
74
. 
APOBEC3B was shown to be one of the underlying enzymatic sources of these types of 
mutations in breast cancer
75,76
. The overexpression of APOBEC3B was shown to be 
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associated with increased mutational load
75
, poor outcome in ER-positive breast cancer
77
 and 
an aggressive phenotype in Japanese breast cancers
78,79
. A 29.5 kb APOBEC3B deletion 
polymorphism results in the complete removal of the APOBEC3B coding region and 
generates a novel fusion transcript with a protein sequence of APOBEC3A, but with a 3’UTR 
of APOBEC3B. The 29.5 kb APOBEC3B deletion polymorphism has been associated with 
increased breast cancer risk in different populations
80-82
 and potentially also result in a 
hypermutator phenotype and loss this polymorphism counterintuitively also correlated with 
an increased mutational load
83
. In this respect, we hypothesized that the APOBEC3B deletion 
polymorphism might also be associated with clinical outcome of breast cancer patients. In our 
study (Chapter 5), we investigated the association between the APOBEC3B deletion 
polymorphism and clinical outcome of 1,756 breast cancer patients. Our study showed that 
the APOBEC3B deletion polymorphism was neither a prognostic nor a predictive biomarker 
for tamoxifen therapy and chemotherapy in breast cancer. We did find a correlation between 
APOBEC3B copy number and APOBEC3B mRNA expression but this correlation was lower 
than expected. In contrast to high levels of APOBEC3B expression, the 29.5 kb APOBEC3B 
deletion polymorphism did not have clinical value. 
The APOBEC3B deletion was also found not to be associated with the survival of breast 
cancer patients by Gohler et al.
84
, however, the patients in that study received various kind of 
treatments. In our study we specifically analyzed pure prognosis and response to tamoxifen 
treatment and chemotherapy, separately. Our results showed that the APOBEC3B deletion 
polymorphism was not a prognostic biomarker for breast cancer. Furthermore, we did not 
find any predictive value of the APOBEC3B deletion polymorphism for the type of response 
to chemotherapy and tamoxifen therapy. The sample size of the patients who received first- 
line chemotherapy was small, so the predictive value to first-line chemotherapy should be 
revisited in larger studies.  
Furthermore, we observed that the correlation between APOBEC3B copy number and 
APOBEC3B mRNA expression was rather weak. Thus, APOBEC3B copy number is not the 
only mechanism to regulate the mRNA level of APOBEC3B. Multiple groups have reported 
higher levels of APOBEC3B mRNA to be prognostic in ER-positive breast cancer patients 
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only and APOBEC3B expression was also predictive for tamoxifen resistance
85
. These 
findings suggested that APOBEC3B particularly plays an important role in ER-positive breast 
cancer but it does not explain how APOBEC3B expression is controlled. The signaling 
pathway responsible for APOBEC3B upregulation might be the PKC-NFκB signaling 
pathway
86
. PKC and NF-κB inhibitors could suppress breast cancer mutagenesis and tumor 
evolution, therefore the inhibition of the PKC/NF-κB signaling pathway may be a target for 
primary tumor treatment. Recently, DNA replication stress caused by cytotoxic agents or 
oncogenic signaling was also shown to modulate APOBEC3 activity which implicated the 
ability of therapeutics
87
. In a future study, it is important to unravel the mechanism of 
APOBEC3B upregulation as the members involved in the pathway could be a target for breast 
cancer therapy.  
Mutational signature 2 and 13 in breast cancer are attributed to the AID/APOBEC family. 
Next to APOBEC3B, other APOBEC members have also been connected to these mutational 
signatures. APOBEC3A could also mediate somatic mutations and APOBEC3A-mediated 
mutagenesis is much more frequent the mutagenesis due to APOBEC3B
88
. Recently, 
APOBEC1
89
 and APOBEC3H
90
 have been proven to contribute to APOBEC mutagenesis in 
breast cancer. These members may be involved in the increased mutational load in various 
breast cancer subtypes and the roles of these APOBEC members in breast cancer need to be 
investigated in the future.  
Tumors with the 29.5 kb APOBEC3B deletion polymorphism were detected to show 
predominantly APOBEC3A-like mutational signatures
88
. The role of elevated levels of 
APOBEC3B mRNA expression and the APOBEC3B deletion polymorphism are likely 
different. APOBEC3B mRNA expression was strongly associated with cellular proliferation, 
while the 29.5 kb APOBEC3B deletion polymorphism was related to immune activation
91
. 
We have found that APOBEC mutagenesis in general lead increased immune-response gene 
expression and tumor infiltrate
92
. APOBEC3B does play a role in innate cellular immunity 
against retroviral infections and the retrotransposition of endogenous elements
93,94
. Absence 
of APOBEC3B was linked to immune response-related gene expression
91,95
 and APOBEC3B 
deletion carriers also had increased tumor-infiltrating immune cells
95
. Increasing lymphocytic 
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infiltration was reported to be associated with excellent prognosis in node-positive, ER- 
negative/HER2-negative breast cancer
96
. In line with this observation, the APOBEC3B 
deletion polymorphism may be a predictor for anticancer immunotherapy
91
. The novel fusion 
transcript presumably acts like APOBEC3A in breast cancer. However, the role of the 
APOBEC3A in breast cancer is still unclear. Therefore, the role of the APOBEC3B deletion 
polymorphism and the novel fusion transcript should be investigated in more studies. 
 
7.2.2 Discovering the predictive value of GATA3 mutations and expression 
Breast cancer arises due to genetic mutations including somatic and germline mutations, 
while sporadic breast cancer develops only from somatic mutations. A large number of 
somatic mutations have been identified particularly through recent large genome sequencing 
studies and two different types of somatic mutations are recognized: ‘driver’ and ‘passenger’ 
mutations. Until today, around 140 genes that contain driver mutations have been 
identified
97,98
. All of the identified driver genes can be classified into 12 signaling pathways. 
A mutation in GATA3 is a frequent breast cancer-specific driver event and GATA3 is involved 
in transcriptional regulation. GATA3 belongs to a family of zinc-finger transcription factors 
and plays an important role in the embryogenesis of a variety of tissues
99-103
. GATA3 is one of 
the most frequently mutated genes (i.e. around 15% in ER
+
 subtype) among breast cancers
104
. 
Many studies have shown that both GATA3 mRNA and GATA3 protein expression were 
independent favorable prognostic markers in breast cancer
105-107
. Moreover, GATA3 was 
suggested to be predictive of a favorable response to hormone therapy
108
 and chemo- 
therapy
109
. GATA3 is a highly conserved gene. The vast majority of the GATA3 mutations are 
found in exons 5 and 6, which encode a zinc finger and the C-terminal domain
110-112
. GATA3 
mutations were observed mostly in ER-positive tumors and correlated with improved overall 
survival in ER-positive breast cancer patients who received adjuvant endocrine therapy
113
. 
Recently, mutant GATA3 was shown to be correlated with suppression of proliferation upon 
aromatase inhibitor treatment
114
. These findings suggested that mutant GATA3 might predict 
response to tamoxifen treatment. To investigate this hypothesis, we analyzed GATA3 
mutations in 235 ER-positive breast cancer cases who received tamoxifen as a first line 
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therapy for recurrent disease (Chapter 6). We did not identify an association of GATA3 
mutations with clinical outcome, which indicated that mutant GATA3 was not a significant 
predictor for tamoxifen therapy in patients with recurrent breast cancer. However, we found 
that GATA3 mRNA expression was associated with an increased progression-free survival 
which implied that GATA3 mRNA expression was predictive for the type of response to 
tamoxifen therapy.  
In the very small study of Parikh et al., 14 patients with ER-positive hormone- 
unresponsive patients were compared with 14 ER-positive hormone-responsive patients and 
found high levels of GATA3 was also predictive of hormone response in ER-positive breast 
cancer patients
108
. Thus, this and our study in Chapter 6, underline a predictive role for 
GATA3 expression. Still considering the size of both studies the current finding requires 
validation in an appropriate independent dataset.  
Apart from the clinical association, we observed that GATA3 mutations were associated 
with increased levels of GATA3 mRNA expression, an observation that was confirmed by 
others in an independent cohort
92
. Importantly, the major fraction of the GATA3 high breast 
cancers did not harbor a GATA3 mutation and GATA3 mutations thus only explained a small 
part of the high GATA3 mRNA expression levels. Therefore, there must be other mechanisms 
besides GATA3 mutations to explain GATA3 overexpression. As a transcription factor, GATA3 
can interact with various other factors to control its downstream pathway(s). Genetic of 
epigenetic regulation of proteins in these cascades may regulate the expression of GATA3. 
GATA3 expression was recently reported to be increased by Wnt/β-catenin pathway activation 
in preadipocytes
115
. Moreover, GATA3 activity was shown to be modulated by ZPO2. More 
specifically ZPO2 when associated with ZBTB32 could downregulate the expression of 
GATA3 and as a result promote aggressive breast cancer development. ZPO2 is therefore a 
possible candidate gene for future diagnostic and, if found clinically relevant, therapeutic 
strategies
116
. In the future study, expression of GATA3 could related with ZPO2 expression in 
our breast cancer patient cohort and if a positive relation was found to determine their 
predictive value for response to tamoxifen. Identification of these factors may lead to a better 
understanding of GATA3 expression regulation and its mechanistic role in resistance to 
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tamoxifen treatment. To understand the predictive value of GATA3 mRNA expression, 
additional studies in clinical cohorts are needed for validation of the current findings and 
more mechanistic studies to reveal its mechanistic role.   
 
7.3 General conclusion 
In conclusion, to facilitate early detection of breast cancer, it is necessary to improve risk 
prediction models that are useful for early detection of breast cancer by identification of 
novel breast cancer risk genes/alleles. In our studies, two recurrent HOXB13 mutations in the 
Dutch population and NBS1 rs2735383 in the European and Asian populations were not 
associated with increased breast cancer risk. Furthermore, to improve personalized treatment 
it is necessary to discover new prognostic and predictive biomarkers for breast cancer. We 
found that the 29.5 kb APOBEC3B deletion polymorphism was neither a prognostic nor a 
predictive biomarker for breast cancer. Furthermore, GATA3 mRNA expression, but not 
GATA3 mutation, is an independent predictor for first-line tamoxifen therapy. We concluded 
sufficiently that NBS1 rs2735383 was not associated with increased breast cancer risk, and 
the 29.5 kb APOBEC3B deletion polymorphism showed no prognostic value nor predictive 
value to first-line tamoxifen therapy. However, the status of one of the two recurrent 
HOXB13 mutations, p.R217C, the predictive value to first-line chemotherapy of the 29.5 kb 
APOBEC3B deletion polymorphism and the predictive role for GATA3 mRNA expression 
should be validated in larger studies. Lager studies for validation and more studies to 
understand the mechanisms are necessary in the future.  
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Summary 
Breast cancer is the second leading cause of deaths by cancers worldwide. The incidence of 
breast cancer is rising in most countries, while survival of patients with breast cancer has 
improved. Breast cancer is a genetic disease and arises as a consequence of genetic mutations 
including both sporadic driver mutations and germline breast cancer susceptibility alleles. 
Breast cancer is also a heterogeneous disease and prognostic and predictive biomarkers are 
important to provide patients with personalized treatment.  
In the first part of the thesis (Chapter 3 and 4), we aimed to discover new breast cancer 
susceptibility alleles. In Chapter 3, we evaluated whether mutations in the HOXB13 gene 
were associated with breast cancer risk. The HOXB13 gene encodes a transcription factor and 
is important in tumorigenesis. The rare variant p.G84E in the HOXB13 gene was reported to 
be associated with an increased risk to develop prostate cancer, while in breast cancer, a high 
HOXB13:IL17BR ratio was found to be a prognostic and predictive biomarker for ER- 
positive breast cancer patients. Based on these findings, we hypothesized that HOXB13 might 
also be a breast cancer susceptibility gene. We firstly analyzed the entire HOXB13 coding 
sequence in 1,250 non-BRCA1/2 familial breast cancer cases and 800 controls and identified 
two predicted deleterious missense mutations, p.G84E and p.R217C. Then, in total 4,520 
familial non-BRCA1/2 breast cancer cases and 3,127 controls were further genotyped for 
these two recurrent mutations. The prostate cancer risk allele p.G84E, but also mutation 
p.R217C were found not to be associated with breast cancer risk. Considering the low 
population frequency and the wide confidence intervals for the p.R217C mutation, the 
association may have failed to be detected. Therefore, it is recommended that p.R217C is 
evaluated in a larger study.  
In Chapter 4, we investigated whether the single nucleotide variant NBS1 rs2735383 
was associated with an increased breast cancer risk. The DNA damage response (DDR) 
pathway maintains human genome stability and plays an important role in susceptibility to 
breast cancer. NBS1 is involved in double-strand break repair and germline NBS1 mutations 
are associated with the risk to develop several types of cancer. The germline NBS1 mutation 
c.657del5 was shown to be associated with breast cancer risk. The genotype of functional 
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variant rs2735383, localized in the 3’UTR of NBS1, regulates the expression level of the 
NBS1 gene by influencing the binding ability of several microRNAs. Furthermore, rs2735383 
has been reported to be associated with lung cancer and colorectal cancer risk. The 
association of NBS1 rs2735383 with breast cancer risk was yet unclear. Therefore we aimed 
to investigate this association. We analyzed NBS1 rs2735383 by RFLP-PCR in 1,159 controls 
and 1,269 cases of the Rotterdam Breast Cancer Study (RBCS) study and found that 
rs2735383 was not significantly associated with breast cancer risk. As the RBCS study was 
relatively small and underpowered to find a small effect size, we additionally analyzed NBS1 
rs2735383 in 47,640 breast cancer cases and 46,656 controls from Breast Cancer Association 
Consortium (BCAC) studies through imputation. For the overall analysis, NBS1 rs2735383 
was not associated with an increased risk to develop breast cancer in Europeans or in Asians. 
Also for the subtype-specific analysis according to age, age at menarche, age at menopause, 
menopausal status, number of full-term pregnancies, breast feeding, family history and 
receptor status, we did not find any association between NBS1 rs2735383 and breast cancer 
risk.  
The results from Chapter 3 and 4 showed that two recurrent HOXB13 mutations in the 
Dutch population and NBS1 rs2735383 in the European and Asian population were not 
associated with increased breast cancer risk.  
 In the second part of the thesis (Chapter 5 and 6), we aimed to discover new prognostic 
and predictive biomarkers for breast cancer. In Chapter 5, the prognostic and predictive 
value of the APOBEC3B deletion polymorphism was evaluated for breast cancer patients. 
APOBEC3B is an endogenous source of mutation in breast cancer and high levels of 
APOBEC3B mRNA has been shown to be associated with a poor prognosis in ER-positive 
breast cancer. A 29.5 kb APOBEC3B deletion polymorphism has also been found to increase 
the mutational load and associate with an increased breast cancer risk. We hypothesized that 
the 29.5 kb APOBEC3B deletion polymorphism was associated with clinical outcome of 
breast cancer patients. To evaluate the prognostic and predictive value, we analyzed the 
APOBEC3B copy number in 1,756 patients who were divided in four cohorts: 528 LNP 
patients who received adjuvant systemic treatment, 1,076 LNN patients who did not receive 
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any adjuvant systemic treatment, 329 ER-positive patients who received tamoxifen as 
first-line treatment for recurrent breast cancer and 226 patients who received first-line 
chemotherapy for recurrent disease. No association between APOBEC3B copy numbers and 
clinical outcome was observed in any of these four cohorts, which implied that APOBEC3B 
copy number was not a prognostic nor a predictive biomarker for breast cancer outcome. We 
further identified that the association between APOBEC3B copy number and APOBEC3B 
mRNA levels was low. 
 In Chapter 6, we evaluated whether the GATA3 mutation was an independent predictor 
for the clinical outcome of breast cancer patients with recurrent disease who had received 
tamoxifen as first-line therapy. GATA3 is a component of the ER pathway and is highly 
expressed in the luminal breast cancer subtype. GATA3 expression has been shown to be an 
independent prognostic marker for breast cancer. Mutated GATA3 was frequently present in 
ER-positive breast cancers and has been associated with the favorable response to 
neoadjuvant aromatase inhibitor treatment. These findings suggested that GATA3 mutations 
may be a predictive biomarker for the type of response to hormonal treatment in recurrent 
breast cancer. We performed sequence analysis for exons 5 and 6 of the GATA3 gene in 235 
ER-positive primary breast cancers and found mutations in 14% of these tumors. However, 
GATA3 mutations were not significantly associated with either the overall response rate or 
with the length of progression-free survival. The GATA3 mutation status was thus not a 
predictor for the type of response to tamoxifen therapy. Out of the 235 tumors, we also 
performed GATA3 mRNA expression analysis for 148 tumors. In contrast to GATA3 mutation 
status, GATA3 expression was shown to be an independent predictor for good prognosis for 
breast cancer patients who received tamoxifen as first-line therapy for recurrent disease.  
 In the second part of the thesis, we found that the 29.5 kb APOBEC3B deletion 
polymorphism was neither a prognostic nor a predictive biomarker for breast cancer outcome. 
Furthermore, GATA3 mRNA expression, but not GATA3 mutation, was an independent 
predictor for the efficacy of first-line tamoxifen therapy. 
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Samenvatting 
Borstkanker is wereldwijd de op een na belangrijkste doodsoorzaak door kanker. De 
incidentie van borstkanker stijgt in de meeste landen nog steeds, terwijl de overleving van 
patiënten met borstkanker verbetert. Borstkanker is een genetische ziekte en ontstaat als 
gevolg van genetische mutaties, zowel sporadische tumor-drijvende mutaties als kiembaan 
borstkanker predispositie allelen. Borstkanker is ook een heterogene ziekte en prognostische 
en predictieve biomarkers zijn belangrijk om patiënten te kunnen voorzien van 
gepersonaliseerde therapie. 
 In het eerste deel van dit proefschrift (Hoofdstuk 3 en 4) was ons doel om nieuwe 
predispositie allelen voor borstkanker te identificeren. In Hoofdstuk 3 hebben we 
geëvalueerd of mutaties in het HOXB13 gen associeerden met een risico op het ontstaan van 
borstkanker. Het HOXB13 gen codeert voor een transcriptiefactor welke belangrijk is tijdens 
de tumorgenese. Er is gerapporteerd dat de zeldzame variant p.G84E in het HOXB13 gen 
geassocieerd was met een verhoogd risico op het ontwikkelen van prostaatkanker, terwijl een 
hoge HOXB13:IL17BR expressieratio een prognostische en predictieve factor is voor ER 
positieve borstkanker patiënten. Gebaseerd op deze bevindingen was onze hypothese dat 
HOXB13 ook een borstkanker predispositiegen kan zijn. Daarom hebben we allereerst de 
complete coderende sequentie van HOXB13 geanalyseerd in het bloed van 1250 
non-BRCA1/2 familiaire borstkankerpatiënten en identificeerden twee terugkerende en 
waarschijnlijk pathogene missense mutaties, p.G84E en p.R217C. Vervolgens werden deze 
terugkerende mutaties gegenotypeerd in een totaal aantal van 4520 familiaire non-BRCA1/2 
borstkankerpatiënten en 3127 controle individuen. Het prostaatkanker risico allel p.G84E, 
maar ook de p.R217C mutatie, bleken niet te associëren met een risico op het ontstaan van 
borstkanker. Wanneer er rekening wordt gehouden met de lage populatiefrequentie en de 
brede betrouwbaarheidsintervallen voor de p.R217C mutatie is het mogelijk dat we niet in 
staat waren om de associatie te detecteren in de huidige situatie. Om deze reden wordt het 
aanbevolen om de p.R217C mutatie nogmaals te evalueren in een grotere studie. 
     In Hoofdstuk 4 hebben we onderzocht of de NBS1 rs2735383 variant associeerde 
met een verhoogd risico op het ontstaan van borstkanker. Het mechanisme dat DNA schade 
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repareert in de cel beschermt de stabiliteit van het genoom en speelt een belangrijke rol bij de 
gevoeligheid voor borstkanker. NBS1 is betrokken bij het herstel van dubbelstrengs DNA 
breuken en kiembaan mutaties in NBS1 associëren met een verhoogd risico op het 
ontwikkelen van verschillende typen kanker. De kiembaan NBS1 mutatie c.657del5 is 
verbonden met een verhoogd risico op het ontwikkelen van borstkanker. Het genotype van de 
functionele variant rs2735383, welke gelokaliseerd is in het 3’ niet getransleerde gebied van 
het NBS1 gen, reguleert de expressie van het NBS1 gen door de bindingsaffiniteit van 
verschillende microRNA’s te beïnvloeden. Daarnaast werd gerapporteerd dat rs2735383 
geassocieerd is met een verhoogd long-en darmkanker risico. De associatie tussen NBS1 
rs2735383 en het risico op het ontwikkelen van borstkanker was nog onbekend. In dit 
hoofdstuk was ons doel deze associatie te onderzoeken. Hiervoor analyseerden we NBS1 
rs2735383 door middel van een RFLP-PCR in bloed van 1159 controle en 1269 aangedane 
individuen uit de Rotterdamse Borstkanker Studie (RBCS) en ontdekten dat rs2735383 niet 
significant associeerde met een borstkanker risico. Omdat RBCS een relatief kleine studie 
was en dus niet genoeg statistische power bevatte om kleine effecten te detecteren hebben we 
NBS1 rs2735383 door middel van imputatie aanvullend geanalyseerd in 47640 
borstkankerpatiënten en 46656 controle individuen van het Borstkanker Associatie 
Consortium (BCAC). In de globale analyse was NBS1 niet geassocieerd met een verhoogd 
risico op het ontwikkelen van borstkanker in Europeanen noch in Aziaten. Ook in de subtype 
specifieke analyses gebaseerd op leeftijd, leeftijd bij menarche, leeftijd bij menopause, 
menopausale status, aantal voldragen zwangerschappen, borstvoeding, familiegeschiedenis en 
hormoonreceptor status vonden we geen enkele associatie tussen NBS1 2735383 en het risico 
op borstkanker. 
 The resultaten van Hoofdstuk 3 en 4 lieten zien dat twee terugkerende HOXB13 
mutaties in de Nederlandse populatie en NBS1 rs2738353 in de Europese en Aziatische 
populatie niet geassocieerd zijn met een verhoogd risico op het krijgen van borstkanker. 
 In het tweede deel van dit proefschrift (Hoofdstuk 5 en 6) was het ons doel om 
genetische markers met prognostische en/of predictieve waarde voor borstkanker te 
ontdekken. In Hoofdstuk 5 werd de prognostische en predictieve waarde van het 29.5 kb 
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APOBEC3B deletie polymorfisme geëvalueerd in borstkankerpatiënten. APOBEC3B is een 
endogene bron van mutaties in borstkanker en hoge APOBEC3B mRNA niveaus associëren 
met een slechte prognose voor patiënten met ER positieve borstkanker. Daarnaast is 
gevonden dat een 29.5 kb APOBEC3B deletie polymorfisme associeert met een verhoogde 
hoeveelheid aan mutaties en een verhoogd borstkanker risico. Onze hypothese was daarom 
dat het 29.5 kb APOBEC3B deletie polymorfisme geassocieerd was met de klinische 
uitkomst van borstkankerpatiënten. Om de prognostische en predictieve waarde te evalueren 
hebben we het aantal kopieën van het APOBEC3B gen bepaald in tumorweefsel van 1756 
patiënten welke voor de analyses opgedeeld werden in 4 cohorten, n.l. 528 
lymfeklier-positieve patiënten die adjuvant systemisch behandeld werden, 1076 
lymfeklier-negatieve patiënten die geen adjuvante systemische therapie ondergingen, 329 
ER-positieve patiënten die behandeld werden met tamoxifen in de eerste lijn voor 
terugkerende ziekte en 226 patiënten die behandeld werden met chemotherapie in de eerste 
lijn voor terugkerende ziekte. We vonden geen associatie tussen het aantal kopieën van 
APOBEC3B en de klinische uitkomst van de patiënten in elk van de vier cohorten. Dit 
impliceerde dat het aantal kopieën van het APOBEC3B gen dus geen prognostische noch 
predictieve waarde heeft voor de uitkomst na de diagnose borstkanker. Verder hebben we 
vastgesteld dat de associatie tussen het aantal kopieën van APOBEC3B en de APOBEC3B 
mRNA expressie laag was. 
 In Hoofdstuk 6 hebben we geëvalueerd of de GATA3 mutatie status een onafhankelijke 
voorspeller is voor de klinische uitkomst van borstkankerpatiënten met terugkerende ziekte 
en welke tamoxifen als eerste lijns therapie ontvingen. GATA3 is onderdeel van het 
ER-signaaltransductiepad en komt hoog tot expressie bij het luminale borstkanker subtype. 
Eerder onderzoek heeft laten zien dat GATA3 expressie een onafhankelijke prognostische 
factor is voor borstkanker. GATA3 is frequent gemuteerd in ER-positief borstkanker en deze 
mutaties bleken geassocieerd met een gunstige respons op de behandeling met neoadjuvante 
aromataseremmers. Deze bevindingen suggereren dat GATA3 mutatie mogelijk een 
predictieve biomarker is voor het type respons op hormonale behandeling bij borstkanker. We 
voerden een sequentie analyse uit voor de exonen 5 en 6 van het GATA3 gen in 235 
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ER-positieve primaire borstkankers and ontdekten mutaties in 14% van de tumoren. Echter, 
GATA3 mutaties associeerden niet significant met de respons op eerste lijns tamoxifen 
therapie of met de lengte van de progressie-vrije overleving na start van de eerste lijns 
behandeling. De GATA3 mutatie status is dus geen voorspeller voor het type respons op 
tamoxifen behandeling. Voor 148 van de 235 tumoren hebben we additioneel 
expressieanalyse voor GATA3 mRNA uitgevoerd. In tegenstelling tot GATA3 mutatiestatus 
vonden we dat GATA3 expressie wel een onafhankelijke voorspeller voor een goede prognose 
is in borstkankerpatiënten met terugkerende ziekte die tamoxifen als eerste lijns therapie 
ontvingen.  
 In het tweede deel van dit proefschrift vonden we dat het 29.5 kb APOBEC3B deletie 
polymorfisme niet een prognostische en ook geen predictieve biomarker was voor 
borstkanker. Daarnaast bleek GATA3 mRNA expressie, maar niet GATA3 mutatiestatus een 
onafhankelijke voorspeller te zijn voor de werkzaamheid van tamoxifen in de eerste lijn.
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